April 29, 2020 |April featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Discngine and Insilico Medicine, as well as recent attempts to combat COVID-19.

The bio-IT community has been working around the clock to address the COVID-19 pandemic. Companies and universities such as MIT, CSIRO, and Oak Ridge National Laboratoryhave concentrated their efforts to develop a COVID-19 Research Database, specialized proteins to combat immune overreaction to the virus, promising animal models, and much more. Roundup

Digital Scienceannounced a partnership with Zhipu.AI to conduct data challenges and collaborate in building a COVID-19 information portal. This strategic collaboration will see the two companies work together on a broad range of projects over the next several years. Some of the existing opportunities planned for the collaboration include joint hosting of a new set of data challenges centered around scholarly communications problems such as name disambiguation; and bringing together advanced analysis tools from both companies to create deeper insights for the sector. Collaboration will be a central theme of the new relationship and will see Digital Science's Overleafmade more seamlessly available to more Chinese users, enabling them to create, edit and publish their research all from one browser using the real-time collaborative LaTeXeditor. Press release

OptraHEALTHannounced that Advagenixhas implemented GeneFAXto assist their patients with accurate information about genetic health. GeneFAX, a flagship product of OptraHEALTH, is an AI-powered HIPAA compliant, knowledge platform for genetic health with BOT interfaces. By employing this AI-enabled technology BOT, AdvaGenix will collect information about their patients family history of cancer as well as understanding reproductive health issues. Patients will then get automatically directed to the right tests to AdvaGenix through GeneFAX. There has been a heavy focus on enabling direct-to-consumer genetic testing over the last few years, but we cannot forget that most of this testing is still being ordered in a clinic. We want to make sure that physicians, genetic labs and patients are at the center of everything we develop, saidDr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH, in a press release. GeneFAX will assistAdvaGenixto better engage with their patients for Hereditary Cancer & Reproductive Genetic Health diagnostic testing andpromote their testing panels in appropriate healthcare settings. Press release

Insilico Medicineannounced it has entered into a research collaboration with Boehringer Ingelheimto utilize Insilico's generative machine learning technology and proprietary Pandomics Discovery Platformwith the aim of identifying potential therapeutic targets implicated in a variety of diseases. "Insilico Medicine is very impressed with the Research Beyond Borders group at Boehringer Ingelheim capabilities in the search of potential drug targets. In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide. We are very happy to partner with such an advanced group," saidAlex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine, in a press release. "We believe that Insilico's exclusive Pandomics platform will provide huge boost to our ability to explore and identify drug targets. We look forward to using AI to significantly improve the drug discovery process and contribute to human health," Dr.Weiyi Zhang, Head of External Innovation Hub, Boehringer Ingelheim GreaterChina, said in an official statement. Press release

Lifebit Biotechannounced a major new release of Lifebit CloudOS, the end-to-end cloud operating system that accelerates genomics research and delivers enriched insights in personalized medicine. Building upon its federated technology, Lifebit CloudOS 2.0 integrates the Biobank Data Browser, allowing users to store and query massive sets of genomic, phenotypic, multi-omic, medical record and other structured data generated by biobanks, such as UK Biobank. Facilitating data exploration, analysis, and discovery, Lifebit CloudOS 2.0 empowers R&D teams to leap forward research and cures. The Biobank Data Browser enables researchers to effortlessly explore and analyze the full complement of genomics and phenotypic data available in biobanks. In addition, the powerful JupyterLabintegration eases barriers to complex data analyses for researchers of all levels. Since it is built to scale to 10+ million individuals and 3+ billion variants, Lifebit CloudOS 2.0 seamlessly handles increasing biobank data collections and data points.More info

Biofourmisannounced it has finalized an agreement to acquire Gaido Healthfrom Takeda Pharmaceuticals, a strategic deal that expands Biofourmis' portfolio in the oncology space. Gaido HealthaLos Angeles-area based digital therapeutics company focused on the oncology marketwas part of Takeda Digital Ventures, Takeda's corporate technology investment and incubation arm. The acquisition seeks to address a disconnected oncology care pathway that has led to more than 30% of patients on chemotherapy being readmitted to the hospital or requiring a visit to the emergency department. Inthe United Statesalone, 1.6 million patients are diagnosed with cancer each year, and the total cost of care is expected to rise to$170 billionin 2020. "Biofourmis' digital therapeutics solution for oncologynow bolstered with this acquisition of Gaido Healthis based on an innovative approach that continuously monitors patients' physiology biomarkers and symptoms, detects early signs of complications, and arms care teams with tools to intervene early to prevent medical crises, improve outcomes and lower costs," said Kuldeep Singh Rajput, CEO of Biofourmis, in a press release. "The platform also empowers patients with cancer to self-manage symptoms using Biofourmis' artificial intelligence [AI]-based Biovitalstreatment algorithms, which improves engagement and quality of life." Gaido Health's solution, which will be supported by Biofourmis' existing Biovitals platform, combines information on vital signs collected via remote monitoring in the home, patient surveys and analytics to detect early signs of complications in patients with cancer who have been recently discharged from the hospital. Gaido Health's AI-based algorithms detect signs of complications to inform the clinician, enabling earlier interventions. Press release

VeracyteandYale Universityannounced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF). The agreement gives Veracyte rights to a 52-gene signature developed by Yale researchers, for use on the nCounter FLEX Analysis System Veracytes exclusively licensed diagnostics platform. Veracyte plans to make the non-invasive, blood-based test available as a complement to its Envisia Genomic Classifier, as part of a comprehensive offering to aid in the diagnosis and treatment of patients with IPF. The 52-gene signature in peripheral blood, developed by Dr. Naftali Kaminski, chief of the Section of Pulmonary, Critical Care and Sleep Medicine in the Department of Medicine at Yale Universitys School of Medicine, and collaborators, is shown to predict rapid disease progression among patients with IPF. We are excited to advance groundbreaking research from Dr. Kaminski and his team into a commercially available, first-of-its-kind genomic test that may further help guide care for patients with IPF, said Bonnie Anderson, Veracytes chairman and chief executive officer, in a press release. The addition of prognostic information to our Envisia classifier, which is already available as a genomic tool to help improve IPF diagnosis, enhances the value of this test for physicians and patients as we prepare it for global market expansion on the nCounter platform in 2021. This agreement was enabled by Veracytes December 2019 acquisition of the exclusive global diagnostics rights to the nCounter platform, and further underscores the strategic value of that transaction to our company. Press release

Scopio Labsannounced it has received CE mark certification for its X100 Full Field Peripheral Blood Smear (Full Field PBS)all-digital morphology analysis platform. As the first digital microscope to scan and analyze entire regions of interest from a slide in high resolution, Full Field PBS enables remote consultation and includes a computer-vision based decision support system, advancing manual microscopy into the digital age. Accelerating the diagnostic process by scanning and digitizing large areas of the slide in high resolution, Scopio Labs helps facilitate efficient review of digital slides and uses its built-in AI tools to compile a detailed report that can also be remotely shared with experts. The Full Field PBS offers an end-to-end decision-support tool for clinicians. Its digitized scans are reconstructed with cutting-edge computational photography tools at 100X equivalent magnification and at oil-immersion resolution levels. Built-in machine learning tools then pre-classify cells within the slide and create a data summary of the results. The image data, as well as the data summary, can be reviewed by experts in multiple locations in the lab that generated the samples, and in other labs within the organization's network. Scopio Labs platforms are scalable, suit a variety of both large and small labs, easily integrate with standard processes and are market-ready. Press release

Discngineannounced that Sosei Heptareshas selected its 3decisionsoftware to be part of a structural GPCR chemogenomics platform. Sosei Heptares will use 3decision to unify the public Protein Data Bank (PDB)structures with internal unpublished GPCR structures used for structure-based drug discovery, thus allowing Sosei Heptares to combine the wealth of its unique structural information, sequence information and knowledge of chemical ligand space in GPCRs. 3decision will enable Sosei Heptares scientists to derive unprecedented structural GPCR insights more efficiently from the structural data at hand. This knowledge will directly benefit the internal structure-based drug design (SBDD) projects and help to further reinforce Sosei Heptares strong expertise in GPCR structural cheminformatics. In addition, 3decision will make it easier for Sosei Heptares to combine the unique structural information with GPCR modelling, cheminformatics capabilities, mutagenesis data and the information provided by their StaR (Stabilized Receptor) technology. For example, 3decision will allow Sosei Heptares to easily visualize and analyze mutagenesis data in 3D, via a web-accessible front-end. Press release

Genomenonannounced that the latest release of theMastermind Genomic Search Engineincludes the ability to search by therapy. Mastermind users can now query the comprehensive database of genomic evidence for over 180,000 drugs, therapies, and other interventions. This new offering furthers Genomenons ability to catalogue a complete dataset of all Genomic Associations supported by medical evidence. These associations help clinical labs more accurately and rapidly diagnose patients, and pharmaceutical companies make ground-breaking discoveries in the effective treatment of cancer and other genetic diseases. Mastermind was launched in 2017 with the ability to uncover associations between diseases, genes, and variants, and has since addedACMG/AMP classification,phenotypes, and now therapies. Each new component of association data increases the power of Mastermind to allow users to find genetic evidence, test or generate hypotheses, and draw clinical conclusions with confidence. Searching by therapy provides significant value for oncologists making decisions on third-line therapies, where approved drugs or clinical trials are no longer effective for a cancer patient. Finding a comprehensive list of all therapies in the medical research tied to a cancer patients genetic make-up is invaluable for treating these late-stage cancer patients. The new search capability is also highly useful for clinicians making diagnostic and treatment decisions for patients with rare diseases. There are currently less than 800 FDA approved therapies for over 7,000 rare diseases, leaving many patients without an approved treatment option. In these cases, clinicians are required to scour the medical literature to find therapies associated with the patients genetic profile; a time-consuming and often fruitless task. Press release

See the rest here:
COVID-19, Insilico Medicine, Discngine, And More: News From April 2020 - Bio-IT World

Recommendation and review posted by Bethany Smith

DENVER, April 29, 2020 /PRNewswire/ --CCRM Fertility, a global pioneer in fertility science, research and advancement, today announced each of its 11 locations across the U.S. will resume all fertility treatments in accordance with new guidance set forth by American Society for Reproductive Medicine (ASRM) on April 24. Effective immediately, all CCRM Fertility locations are open and seeing both new and existing patients for all treatments, including egg retrievals, embryo transfers, and intrauterine inseminations (IUI), regardless of where they began their fertility journey prior to the global pandemic-related lockdown.

"At CCRM Fertility, we are dedicated to giving families the very best chance to have a baby, but the previous recommendations outlined by ASRM as a result of the novel coronavirus unfortunately paused treatment plans for many patients,"comments CCRM Fertility Founder and Medical Director William Schoolcraft, M.D."We know that the delays caused by COVID-19 have been heartbreaking for our patients, and this new guidance allows us to resume treatment for all patientsso they may continue their journeys toward parenthood as quickly and as safely as possible."

CCRM Fertility is committed to not only helping individuals and couplesbuildtheir families, but also protecting the health and wellbeing of its patientsand staff.In order to continue to provide industry-leading care and outcomes while limiting social exposure and virus transmission, CCRM Fertility has implemented the following measures:

All CCRM Fertility physicians and medical directors will continue monitoring the evolving situation and will stay in close communication with patients. For CCRM Fertility's most up-to-date policies and guidelines on COVID-19, visit ccrmivf.com/covid19/.

To schedule an appointment, call (877) 201-6931 or visit http://www.ccrmivf.com.

About CCRM Fertility

Founded by Dr. William Schoolcraft in 1987, CCRM Fertility is the nation's leader in fertility care and research. CCRM Fertility specializes in the most advanced fertility treatments, with deep expertise in in vitro fertilization (IVF), fertility assessment, fertility preservation, genetic testing, third party reproduction and egg donation. Unlike many other fertility clinics that outsource their specialists and testing needs, CCRM Fertility leverages its own data, as well as a dedicated team of in-house reproductive endocrinologists, embryologists and geneticists in order to deliver industry-leading outcomes. CCRM Fertility operates 11 fertility centers (including 26 offices) throughout North America, serving prospective parents in major metropolitan areas, including Atlanta, Boston, Dallas, Denver, Houston, New York, Northern Virginia, Minneapolis, Orange County, San Francisco Bay Area and Toronto. For more information, visit http://www.ccrmivf.com, become a fan on Facebook, or follow us onInstagram and Twitter.

More here:
CCRM Fertility Resumes All Forms of Treatment for New and Existing Patients - The Grand Junction Daily Sentinel

Recommendation and review posted by Bethany Smith

LITTLE ROCK, Ark. As Governor Asa Hutchinson prepares to announce decisions for when businesses forced to close by the COVID-19 outbreak could possibly restart, there's uncertainty among business leaders.

A trio of Little Rock company owners touched on that uncertainty while being honored by the local Rotary Club for the way they adapted to the outbreak.

"It's been chaos," said Steve Harrison, head of Natural State Labs, which went from genetic testing to drive-up virus testing in a matter of days. "I think is the best way to describe it."

Harrison joined Phil Brandon of Rock Town Distillery, Patrick Schueck of Lexicon Constructors and Fabricators, and Larry Whitman, an engineering professor at UA-Little Rock.

RELATED: Gov. Hutchinson announces plans to reopen state parks, marinas in May

"That's the $64,000 question," said Brandon, who joined many other brewers and distilleries in switching to making hand sanitizer to avoid going from booze to bear market overnight.

"The hand sanitizer we make is primarily alcohol, and we make alcohol everyday. I think the demand is going to be there for quite a while and we'll keep making it as long as there's a market for it."

Dean Whitman and Schueck talked about collaborating to ramp up production of face shield components to meet the demand for personal protective equipment.

RELATED: Little Rock Goodwill housing giant disinfecting units to help recycle PPE

They along with Harrison managed to stay open, though under the "targeted approach" used by the governor, didn't face pressure to shut down. They all spoke of how quickly events unfolded and how quickly they had to respond.

"It's been kind of the wild wild west in terms of where this is going to go," said Harrison, who is now hustling to provide required 48-hour virus testing for the many people green-lighted to get delayed elective surgery.

While those patients rush in, not everyone is in a hurry.

"Some would like to see the restaurants and barber shops in their community opened yesterday. Some would like to see it delayed," the governor said of responses he's heard from mayors ahead of his decision days.

A similar split exists in the business community.

"I think it's pretty evenly divided across the board," said Jay Chesshir, the president of the Little Rock Regional Chamber of Commerce and moderator of the Rotary Club panel. "The want-to and the intent and the desire is there. They just want to do so in a safe manor."

Link:
Arkansas businesses uncertain ahead of governor's announcements to reopen state - THV11.com KTHV

Recommendation and review posted by Bethany Smith

Psomagen, a US company dedicated to genome sequencing technology and DNA testing, said on April 29 it looks to raise at least 57.5 billion won ($47.2 million) in an initial public offering on the Korean bourse.

Under the plan to be listed on Kosdaq, Psomagen seeks to issue 4.2 million new common shares, amounting to a 25 percent stake, and offer them to investors in an IPO set to take place in May. Shinhan Investment is an underwriter of the IPO deal.

The IPO proceeds will be used to boost its entry into a personal genomics business targeting the US market, repay its debt for an acquisition deal and ramp up its logistics infrastructure for its end-to-end genome sequencing solutions.

Psomagen CEO Ryan Kim speaks at a briefing held in Seoul on April 29. (Psomagen)

Psomagens foray into personal genomics business is crucial, as the practice of a precision medicine is increasingly tailored to an individual, Psomagen CEO Ryan Kim told reporters on April 29 in a briefing in Seoul.

(Psomagen) is turning into a health care solution provider powered by big data, based on our genome sequencing capability, he said.

We are witnessing a paradigm shift in US health care system. As the genome sequencing technology gets more sophisticated, its price has been on the decline, so individual health care services are increasingly tailored to analysis and interpretation of the genome of an individual.

Based in Rockville, Maryland, Psomagen has moved to produce genetic testing kits using saliva samples and sell them directly to consumers. It also tapped into microbiome genetic testing solutions using consumers stool samples.

This is a leap forward from its decadeslong effort to focus on research into genome sequencing using technologies such as sanger sequencing and next-generation sequencing.

Having both the College of American Pathologists accreditation and Clinical Laboratory Improvement Amendments certification, the company was the only for-profit entity to join former US President Barack Obamas Trans-Omics for Precision Medicine initiative, according to Psomagen. Kim said the research division is expected to generate a steady return of profits.

The efforts will also be buttressed by its latest acquisition of San Francisco-based biotech company uBiome in 2019, which allowed Psomagen to possess its 246 patent rights and some 300,000 data subjects.

In 2019, Psomagen logged a $4.17 million operating loss and 19.79 million net loss, according to its prospectus. The net loss rose over eightfold largely due to the cost of the uBiome acquisition deal.

Psomagen is expected to become the first company based out of Korea to go public by undergoing an abridged screening procedure by the Korea Exchange. The procedure, special listing on promising business model, allows a companys listing eligibility to be evaluated by the potential of scalability instead of profitability.

Psomagen is a spinoff from Seoul-based genomics service provider Macrogen. If the new shares are issued, Macrogen and its affiliated shareholders will hold a combined 68.7 percent stake. It is part of the 71.53 percent of shares that will be placed under a lockup period for one to three years.

By Son Ji-hyoung (consnow@heraldcorp.com)

Follow this link:
US-based Psomagen eyes at least W57.5b IPO in Korea - The Investor

Recommendation and review posted by Bethany Smith

In this report, the global Predictive Genetic Testing market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Predictive Genetic Testing market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Predictive Genetic Testing market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Predictive Genetic Testing market to assist our clients arrive at beneficial business decisions.

The Predictive Genetic Testing market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Predictive Genetic Testing market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/31204

Resourceful insights enclosed in the report:

The major players profiled in this Predictive Genetic Testing market report include:

key players in the predictive genetic testing market. The significant competitive strength of the existing players in the evolving landscape of the global predictive genetic testing market is anticipated to offer new prospect in widening the application of the predictive genetic testing, substantially driving predictive genetic testing market growth. The key manufacturers of the predictive genetic testing are greatly concentrated on the technical edification of the end users to improve consumer outcomes. Furthermore, the adoptions of advanced predictive genetic testing services is expected to create lucrative growth opportunities for the service and third-party market competitors. Growing inclination toward trend in predict is prevention is estimated to offer growth opportunity for Predictive genetic testing market. Selection of treatment regimen with Predictive genetic testing is projected to aid capturing higher share in Predictive genetic testing market.

Geographically, global Predictive genetic testing market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia Oceania and Middle East & Africa. North America is prominent region in Predictive genetic testing Market. Advancement in genetic care facilities, higher adoption to lifestyle changes, increase awareness about genetic disease, increase in preventative care and favorable government policies have improved the regulatory scenario for predictive genetic testing devices in north America. Additionally in Asia pacific region considerably higher market growth rate is expected due to constantly rising population and higher incidence of genetic abnormality. Relatively affecting the Predictive genetic testing market.

Some of the major key players competing in the global Predictive genetic testing Market are Myriad Genetics, Inc., Abbott Laboratories, Illumina, Inc., Genesis GeneticsThermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., , Agilent Technologies, F. Hoffmann-La Roche Ltd., Counsyl, Inc., ARUP Laboratories. BGI among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/31204

The market report addresses the following queries related to the Predictive Genetic Testing market:

The study objectives of Predictive Genetic Testing Market Report are:

To analyze and research the Predictive Genetic Testing market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Predictive Genetic Testing manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Predictive Genetic Testing market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Predictive Genetic Testing market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/31204

Read more from the original source:
The Economic Impact of Coronavirus on Predictive Genetic Testing Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2065 2019 2029 - Latest...

Recommendation and review posted by Bethany Smith

The report delivers the driving factors, challenges, restraints, opportunities, acquisition & merger, revenue structure, business models, market players, segmentation, regional analysis, production price, manufacturing process, operations, methodology, market share, market size, CAGR, and investments.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/3856288

Manufacturer Detail

Manufacturer DetailAugury SystemsBosch Software Innovations GmbhC3 IotDell Technologies, Inc.Fluke CorporationGeneral Electric CompanyHitachi, Ltd.Honeywell International, Inc.Ibm CorporationPtcRapidminer, Inc.Rockwell Automation, Inc.Sap SeSas Institute, Inc.Schneider ElectricSenseye, Ltd.SkfSoftware AgSoftweb Solutions, Inc.T-Systems International GmbhWarwick Analytics

BIS reports covers key roles in analyzing the industry outlook and let understand the prominent vendors about their strategies and future plans for the betterment of the market in the near future. Furthermore, the report also covers an ultimate goal of market target gained on the basis of product or services. In this Preimplantation Genetic Testing market report, viewers can also experience detailed study of business introduction including benefits, restraints, opportunities, challenges, drivers, and more. The report smartly takes you to productive methodology in organizing, collection, and analyzing data. The report covers key aspects including production, market share, CAGR, key regions, leading vendors, and revenue rates. This keyword report also provides viewers with relevant figures at which the Preimplantation Genetic Testing market was valued in the base year and estimated to project the revenue in the forecasted period. The Preimplantation Genetic Testing market is categorizes several segmentations including type, application, end user industry, and region. This effective set of information delivers an in-depth analysis about the drivers, challenges, market share, market dynamics, emerging countries, pricing, investment activity, industry performance, revenue generation and CAGR.

Region Segmentation

North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Product Type SegmentationPreimplantation Genetic Screening (Pgs)Preimplantation Genetic Diagnosis (Pgs)Industry SegmentationAneuploidyStructural Chromosomal AbnormalitiesSingle Gene DisordersX-Linked DisordersHla Typing

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-preimplantation-genetic-testing-market-report-2019

Channel (Direct Sales, Distributor) Segmentation

Section 8: 400 USDTrend (2019-2024)

Section 9: 300 USDProduct Type Detail

Section 10: 700 USDDownstream Consumer

Section 11: 200 USDCost Structure

Section 12: 500 USDConclusion

The research report is an overall draft when it comes to understand the investment structure and future analysis of the Preimplantation Genetic Testing market. BIS Report manages to convey detailed information regarding prominent vendors of the Preimplantation Genetic Testing market including recent innovations, advancements, improvements, business estimation, revenue margin, and sales graph.

Consumer-wise, the report studies about the demand coming from particular region and category of consumers taking interest in the product or services of the Preimplantation Genetic Testing market. The global keyword market is majorly driven by key factors and offers an in-depth insight about the keyword market.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/3856288

The Preimplantation Genetic Testing market reports delivers the information about market competition between vendors through regional segmentation of markets in terms of business opportunities, demand & supply, and revenue generation potential.

BIS report envision clear view about Preimplantation Genetic Testing market including regional growth and falls down mentioning about particular forecast period along with appropriate reasoning about the market.

The Preimplantation Genetic Testing market also delivers the market size, market appearances, segmentation, provincial collapses, tendencies, competitive background to gain the appropriate insights. Moreover, the report also covers about the acquisitions and mergers taken in the recent past.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

See the original post here:
Preimplantation Genetic Testing Industry Analysis, by Services, Key Players, Size, Trends and Forecast 2024 - Latest Herald

Recommendation and review posted by Bethany Smith

Direct-to-Consumer (DTC) Genetic Testing Market 2020 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry.

Delivering the key insights pertaining to this industry, the report provides an in-depth analysis of the latest trends, present and future business scenario, market size and share of Major Players such asEasyDNA, Ancestry, 23andMe Inc., Color Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics.

Global direct-to-consumer (DTC) genetic testing market is set to witness a healthy CAGR of 18% in the forecast period of 2019-2026.

Get Sample Report: To Know the Impact ofCOVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global Direct-to-Consumer (DTC) Genetic Testing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Direct-to-Consumer (DTC) Genetic Testing Industry

Market Drivers

High ageing population and growing prevalence of genetic diseases will boost this market growth

Growing customer awareness about the DTC genetic testing acts as a market driver

Tests are effortlessly accessible to the customers around the world; this factor acts as a major market driver

Market Restraints

High charges of DTC genetic testing kits can hamper the growth of this market

Lack of skilled and trained professional is another factor restraining the growth of the market

Scientific, technical and clinical issues along with fidelity to facts and truth-in-advertising can also act as restraining factor for the growth of this market

Complete report is available @https://www.databridgemarketresearch.com/toc/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

For an excellent outcome of Direct-to-Consumer (DTC) Genetic Testing report, qualitative and transparent research studies are carried out devotedly for the specific niche. Being a global market research report, it also identifies, analyses, and estimates the emerging trends along with major drivers, challenges and opportunities in the industry and analysis of vendors, geographical regions, types, and applications. An idea about competitive landscape plays very important role in deciding about the improvements required in the product and more. As businesses can achieve thorough insights with this report, they can confidently take decisions about their production and marketing strategies.

The titled segments and sub-section of the market are illuminated below:

Region Included are:United States, Europe, China, Japan, Southeast Asia, India & Central & South America

By Service: Diagnostic Screening, Prenatal, Newborn Screening, Pre-Implantation Diagnosis

By Product Type: Ancestry, Health and Wellness, Entertainment

By Business Model: Genome Data Bank Material Model, Individual Health Planning Model

Top Players in the Market are: EasyDNA, Ancestry, 23andMe Inc., Color Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics.

How will the report help new companies to plan their investments in the Direct-to-Consumer (DTC) Genetic Testing market?

The Direct-to-Consumer (DTC) Genetic Testing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies of.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Direct-to-Consumer (DTC) Genetic Testing Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Direct-to-Consumer (DTC) Genetic Testing Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 281

TheGlobal Direct-to-Consumer (DTC) Genetic Testing Marketstudy with 100+ market data Tables, Pie Chat, Graphs & Figures is now released by Data Bridge Market Research. The report presents a complete assessment of the Market covering future trend, current growth factors, attentive opinions, facts, and industry validated market data forecast till 2026. Delivering the key insights pertaining to this industry, the report provides an in-depth analysis of the latest trends, present and future business scenario, market size and share of Major Players such asEasyDNA, Ancestry, 23andMe Inc., Color Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics.

Global direct-to-consumer (DTC) genetic testing market is set to witness a healthy CAGR of 18% in the forecast period of 2019-2026.

Get Sample Report: To Know the Impact ofCOVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global Direct-to-Consumer (DTC) Genetic Testing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Direct-to-Consumer (DTC) Genetic Testing Industry

Market Drivers

High ageing population and growing prevalence of genetic diseases will boost this market growth

Growing customer awareness about the DTC genetic testing acts as a market driver

Tests are effortlessly accessible to the customers around the world; this factor acts as a major market driver

Market Restraints

High charges of DTC genetic testing kits can hamper the growth of this market

Lack of skilled and trained professional is another factor restraining the growth of the market

Scientific, technical and clinical issues along with fidelity to facts and truth-in-advertising can also act as restraining factor for the growth of this market

Complete report is available @https://www.databridgemarketresearch.com/toc/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

For an excellent outcome of Direct-to-Consumer (DTC) Genetic Testing report, qualitative and transparent research studies are carried out devotedly for the specific niche. Being a global market research report, it also identifies, analyses, and estimates the emerging trends along with major drivers, challenges and opportunities in the industry and analysis of vendors, geographical regions, types, and applications. An idea about competitive landscape plays very important role in deciding about the improvements required in the product and more. As businesses can achieve thorough insights with this report, they can confidently take decisions about their production and marketing strategies.

The titled segments and sub-section of the market are illuminated below:

Region Included are:United States, Europe, China, Japan, Southeast Asia, India & Central & South America

By Service: Diagnostic Screening, Prenatal, Newborn Screening, Pre-Implantation Diagnosis

By Product Type: Ancestry, Health and Wellness, Entertainment

By Business Model: Genome Data Bank Material Model, Individual Health Planning Model

Top Players in the Market are: EasyDNA, Ancestry, 23andMe Inc., Color Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics.

How will the report help new companies to plan their investments in the Direct-to-Consumer (DTC) Genetic Testing market?

The Direct-to-Consumer (DTC) Genetic Testing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies of.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Visit link:
Direct-to-Consumer (DTC) Genetic Testing Market (COVID-19 Impact Analysis)2020 Global Industry Analysis, Size, Growth, Trends, Share and Forecast...

Recommendation and review posted by Bethany Smith

XconomyTexas

Some former executives and investors behind the second gene therapy to win FDA approval are teaming up again. Their new company, Taysha Gene Therapies, is launching with $30 million in the bank and a plan to bring its first central nervous system (CNS) disorder program into human testing later this year.

Taysha is focusing on monogenic CNS diseases, which are caused by a single mutation in a single gene, says president and CEO RA Session II. The Dallas-based startup is developing treatments for rare genetic diseases as well as conditions that affect larger segments of the population, such as epilepsy and neurodegenerative disorders.

As long as its a monogenic CNS disease, were going to go after it, Session says.

Taysha has a pipeline of 15 gene therapies, and an option to add four more. The experimental treatments come from the University of Texas Southwestern (UTSW) Medical Center, which has a gene therapy program led by Steven Gray and Berge Minassian. Session, a former pharmaceutical industry executive who is currently an entrepreneur in residence at UTSW, says university administrators asked him to come up with ideas for funding the gene therapy research. Some entities were interested in taking on individual assets, but Sessions concluded that the best way to fund the entire portfolio was to create one company.

Rare diseases represent an unmet medical need, but even when the biology is clear a therapys commercial prospects can be murky. Drugs for chronic conditions can take several years to reach peak sales, but that peak then continues for years as more patients use a product, Session says. In rare diseases, this time to peak is typically achieved in the first year to 18 months of sales. Afterward, revenue falls because a rare disease by definition does not affect a big pool of potential new patients. Session says that in order to be financially sustainable, a drug company needs to constantly launch new products, and the UTSW assets give Taysha the opportunity to do just that.

It helps that Taysha is not starting from scratch. Session is a former business development executive for AveXis, a gene therapy developer that got its start in Dallas. Novartis (NYSE: NVS) acquired AveXis in 2018, and made the company its gene therapy division. Last year, AveXiss Zolgensma won FDA approval for spinal muscular atrophythe second gene therapy to receive the regulators nod.

Gene therapy uses an engineered virus to deliver a functioning gene that replaces a defective one. Tayshas gene therapies will be delivered by adeno-associated virus 9 (AAV9), a virus that can cross the blood-brain barrier. Its the same virus used for Zolgensma and Session says AveXiss work shows that the virus can be given to patients safely and effectively. Also, experience with the viral technology gives the company a leg up on knowing how to manufacture any therapies it produces quickly and at scale, he adds.

The seed financing announced Wednesday will fund Tayshas early work. PBM Capital, the first investor in AveXis, and Nolan Capital, the investment fund of former AveXis CEO Sean Nolan, co-led the round.

Tayshas lead program is TGTX-101, an experimental gene replacement therapy for GM2-gangliosidosis, a rare, inherited enzyme disorder that leads to the destruction of neurons in the brain and spinal cord. Session says this program is expected to begin clinical testing later this year. The company aims to ask the FDA for permission to start clinical trials for three additional gene therapies by the end of next year. Those programs include the mitochondrial disorder SURF1 deficiency; a form of epilepsy caused by a mutation to the SLC6A1 gene; and Rett syndrome, a neurological disorder caused by a genetic mutation.

In addition to advancing new gene therapies, Taysha is also developing new gene therapy technologies. Session says some of the research focuses on new capsids, the protein shells that enclose a virus. These next-generation capsids could potentially get a gene therapy to different cells in the body more efficiently and effectively, which could lead to therapies that require a lower dose, ultimately improving safety, he says.

Taysha is also developing technology for redosing a gene therapy. While these therapies are meant to be long-lasting, their durability over the course of a patients lifetime is still unknown, Session says. Redosing with the same therapy isnt possible because patients develop antibodies to the virus. Taysha is developing a way to redose via a new route of administrationthe vagus nerve. Session declined to elaborate, saying only that its early but its interesting. Its an issue the sector has been grasping at and trying to solve.

AveXis is still developing new gene therapies. A company executive told Xconomy earlier this year that an application to start human tests of a Rett syndrome therapy is expected to be ready by mid-2020. A number of companies on are on AveXiss heels, some of them focused in particular on the central nervous system and the brain. The CNS gene therapies at Passage Bio (NASDAQ: PASG) are from the University of Pennsylvania. New York-based Neurogene is also focused on rare monogenic neurological diseases. Prevail Therapeutics of New York and Voyager Therapeutics (NASDAQ: VYGR) are developing gene therapies for Parkinsons disease.

Taysha will develop its programs in partnership with UTSW. The university is handling discovery and preclinical research, as well as the studies leading up to an application to start clinical trials. UTSW will also handle manufacturing for clinical trials. Taysha will take the lead on clinical testing and regulatory work. If any of the gene therapies win regulatory approval, the company will take over manufacturing and handle commercialization.

Photo by Flickr user Katie Haugland Bowen via a Creative Commons license

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com.

Read the original:
Taysha Launches With $30M to Bring Gene Therapy to CNS Disorders - Xconomy

Recommendation and review posted by Bethany Smith

Biotech executive, Julia Berretta, Ph.D., is named Chief Executive Officer

Genespire, a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, announced today the successful close of a 16M Series A financing from Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan. The company also announced the appointment of Julia Berretta, Ph.D., as Chief Executive Officer and member of the Board of Directors. Graziano Seghezzi, Managing Partner at Sofinnova Partners, and Lucia Faccio, Ph.D., Partner at Sofinnova Partners, will also join the Board.

Genespire was founded in March 2020 as a spin-off of the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), one of the worlds leading cell and gene therapy research institutes spearheaded by gene therapy pioneer Prof. Luigi Naldini. The Company was co-founded by Fondazione Telethon and the San Raffaele Hospital, along with Prof. Naldini and Dr. Alessio Cantore.

The funds will be used to advance Genespires leading-edge platform technologies towards the development of novel gene therapies in two main areas: primary immunodeficiencies and metabolic genetic diseases.

"Our mission has always been to develop breakthrough solutions for genetic diseases," said Prof. Naldini, Genespires co-founder and Director of SR-Tiget. "This financing enables the company to translate our innovative science and early stage programs into clinical development. The appointment of Dr. Berretta as CEO is a major reinforcement of our team."

Sofinnova Partners Dr. Faccio added, "Genespire is an exciting investment with all the key ingredients for success: Outstanding scientists that developed the first ex-vivo gene therapy to market, experienced executives brought in through Sofinnova Partners network and game changing technologies that have the potential to impact the lives of patients with genetic diseases."

"I am thrilled to be joining Genespire and such exceptional scientific founders," said Dr. Berretta. "Genespire was born of decades of experience in the gene therapy field, and is optimally positioned to advance transformative therapies for patients affected by severe inherited diseases."

Dr. Berretta was part of the Executive Committee of Cellectis S.A., a Nasdaq-listed clinical stage gene editing company developing CAR-T cell therapies for cancer, where she led business development as well as strategic planning. She is also an independent Board member of Treefrog Therapeutics, an innovative stem cell company.

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. http://www.genespire.com

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management.

For more information, please visit: http://www.sofinnovapartners.com

About Fondazione Telethon

Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments. For more information, please visit: http://www.telethon.it

Story continues

About Ospedale San Raffaele

Ospedale San Raffaele (OSR) is a clinical-research-university hospital established in 1971 to provide international-level specialised care for the most complex and difficult health conditions. OSR is part of Gruppo San Donato, the leading hospital group in Italy. The hospital is a multi-specialty center with over 60 clinical specialties; it is accredited by the Italian National Health System to provide care to both public and private, national and international patients. Research at OSR focuses on integrating basic, translational and clinical activities to provide the most advanced care to our patients. The institute is recognized as a global authority in molecular medicine and gene therapy, and is at the forefront of research in many other fields. Ospedale San Raffaele is a first-class institute which treats many diseases and stands out for the deep interaction between clinical and scientific area. This makes the transfer of scientific results from the laboratories to the patients bed easier. Its mission is to improve knowledge of diseases, identify new therapies and encourage young scientists and doctor to grow professionally. For more information, please visit: http://www.hsr.it

About the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200429005417/en/

Contacts

Julia BerrettaCEO, Genespire S.r.linfo@genespire.com +39 02 83991300

Bommy LeeHead of Communications, Sofinnova Partnersblee@sofinnovapartners.com +33 (0) 6 47 71 38 11

North AmericaRooneyPartners LLCKate Barrettekbarrette@rooneyco.com +1 212 223 0561

FranceStrategiesImage (S&I)Anne Reinanne.rein@strategiesimage.com +33 6 03 35 92 05

The rest is here:
Genespire Secures 16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies - Yahoo Finance

Recommendation and review posted by Bethany Smith

DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciencesInc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS gene editing platform, today announced that the Company and its collaborators will present at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 12-15, 2020.

The abstracts being presented by Precision and our collaborators this year at ASGCT underscore the differentiated capabilities of our proprietary ARCUS genome editing platform and the breadth of our emerging pipeline applying this technology in vivo, commented Derek Jantz, Chief Scientific Officer and co-founder of Precision BioSciences. These presentations demonstrate the specificity and versatility of ARCUS-driven genome editing in a variety of large animal models and provide further preclinical evidence of potentially meaningful and durable therapeutic impact on a range of genetic and infectious diseases. As we continue to validate ARCUS potential in vivo, we are focused on advancing our gene correction pipeline. We look forward to selecting a clinical candidate for our wholly owned PH1 program, expected in 2020, and, in partnership with Gilead, developing a potential cure for chronic hepatitis B infection, for which submission of an IND is currently targeted for 2021.

Precision BioSciences Presentations:

Title:Engineering a Self-Inactivating Adeno-Associated Virus (AAV) Vector for ARCUS Nuclease DeliveryPoster Session: Gene Targeting and Gene Correction, Abstract: 654Presenting Author: Hui Li, Ph.D., Precision BioSciences

Title:A Gene Editing Approach to Eliminate Hepatitis B Virus Using ARCUS MeganucleasesPoster Session: Gene Targeting and Gene Correction, Abstract 1057Presenting Author: Cassie Gorsuch, Ph.D., Precision BioSciences

Partnered Presentations:

Title: Therapeutic Efficacy of ARCUS Meganuclease Gene Editing - Arrest of Rod Degeneration and Restoration of Rod Function in a Transgenic Pig Model of Autosomal Dominant Retinitis PigmentosaOral Presentation: Gene Therapy for the Special Senses, Abstract 2Date/Time: Tuesday, May 12, 2020, 10:30 10:45 a.m. ESTPresenting Author: Maureen Ann McCall, Ph.D., Professor, Department of Ophthalmology and Visual Sciences, University of Louisville

Title: Evaluation of the Long-term Effects of AAV-Meganuclease Genome Editing of PCSK9 in Macaque LiverOral Presentation: Evaluating Genome Editing Activity and Precision, Abstract 518Date/Time: Wednesday, May 13, 2020, 4:00 4:15 p.m. ESTPresenting Author: Lili Wang, Ph.D., Research Director, Discovery Research and Gene Editing, Research Associate Professor, Department of Medicine, Perelman School of Medicine, University of Pennsylvania

All abstracts for the ASGCT 2020 Meeting are available online at ASGCT Annual Meeting Abstracts.

About Precision BioSciences, Inc.Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, ARCUS. Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For more information regarding Precision, please visitwww.precisionbiosciences.com.

Forward-LookingStatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing of trials and results from clinical and non-clinical studies of our in vivo gene correction program and the safety, efficacy and delivery of our ARCUS genome editing technology. In some cases, you can identify forward-looking statements by terms such as anticipate, believe, could, expect, should, plan, intend, estimate, target, mission, may, will, would, should, could, target, project, predict, contemplate, potential, or the negative thereof and similar words and expressions.

Forward-looking statements are based on managements current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding and requirements under our current debt instruments; our limited operating history; the success of our programs and product candidates; our dependence on our ARCUS technology; the initiation, cost, timing, progress and results of research and development activities, preclinical or greenhouse studies and clinical or field trials; our or our collaborators ability to identify, develop and commercialize product candidates; our or our collaborators ability to advance product candidates into, and successfully complete, clinical or field trials; our or our collaborators ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the laws and regulatory landscape that will apply to our and our collaborators development of product candidates; our ability to achieve our anticipated operating efficiencies as we commence manufacturing operations at our new facility; delays or difficulties in enrolling patients in clinical trials; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriate of intellectual property rights; if our product candidates do not work as intended or cause undesirable side effects the potential for off-target editing or other adverse events, undesirable side effects or unexpected characteristics associated with any of our product candidates; risks associated with applicable healthcare, data privacy and security regulations and our compliance therewith; the rate and degree of market acceptance of any of our product candidates; the success of our existing collaboration agreements; our ability to enter into new collaboration arrangements; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields; potential manufacturing problems associated with any of our product candidates; pending and potential liability lawsuits and penalties related to our technology, our product candidates; the outbreak of the novel coronavirus disease (COVID-19); our current and future relationships with third parties; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate key scientific and management personnel; effects of natural or manmade disasters, public health emergencies and other natural catastrophic events; insurance expenses and exposure to uninsured liabilities; market and economic conditions; dilution and fluctuations in our stock price; and other important factors discussed under the caption Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by the risk factor contained in our Current Report on Form 8-K filed with the SEC on April 6, 2020, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SECs website atwww.sec.gov.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contacts:Nick RiddlePrecision BioSciencesTel. (919) 314-5512IR@precisionbiosciences.com

Josh RappaportStern Investor RelationsTel. (212) 362-1200josh.rappaport@sternir.com

Media Contact:Maurissa MessierPrecision BioSciencesTel. (919) 314-5512media@precisionbiosciences.com

View post:
Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting - BioSpace

Recommendation and review posted by Bethany Smith

~22 Presentations at ASGCT, Including New Preclinical Data on Gene Therapy Candidates, Highlight uniQures Industry-Leading Research and Technology Capabilities ~

LEXINGTON, Mass. and AMSTERDAM, April 28, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 22 data presentations, of which five are oral presentations, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Virtual 2020 Annual Meeting being held May 12-15.

"uniQures significant scientific presence at this years ASGCT Annual Meeting demonstrates the robustness of our research capabilities and our excellence in developing novel technologies and commercial-scale gene therapy manufacturing, stated Sander van Deventer, executive vice president of research and product development at uniQure. We are very pleased to present new preclinical data on our gene therapy candidates for hemophilia A, spinocerebellar ataxia type 3, Fabry disease and data on our advances in technology and manufacturing.

Specific details on uniQures virtual oral presentations at ASGCT include:

Title: One-Time Intrathecal Administration of AAV5-miATXN3 in Non-Human PrimatesDate and Time: Wednesday May 13, 4:15 p.m. EDT/ 10:15 p.m. CET

Title: A Novel NAGA Variant Designed to be Non-immunogenic In Humans and Provide Broad Cross-Correction in Fabry DiseaseDate and Time: Thursday May 14, 4:15 p.m. EDT/ 10:15 p.m. CET

Title: A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable hFIX Expression up to 18 Months after DosingDate and Time: Thursday May 14, 4:15 p.m. EDT/ 10:15 p.m. CET

Title: Characterizing Next-Generation Baculovirus Transduction Processes - A Quality by Design-based Approach for AAV ManufacturingDate and Time: Friday May 15, 10:45 a.m. EDT/ 4:45 p.m. CET

Title: Clearance of Vector DNA From Bodily Fluids in Patients with Severe or Moderate-Severe Hemophilia B Following Systemic Administration of AAV5-hFIX and AAV5-hFIX PaduaDate and Time: Friday May 15, 11:15 a.m. EDT/ 5:15 p.m. CET

The following presentations were approved for poster presentation:

The abstracts were published today at the ASGCT Annual Meeting website.

About uniQure

uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.www.uniQure.com

Originally posted here:
uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting - Yahoo Finance

Recommendation and review posted by Bethany Smith

Dive Brief:

Merck KGaA, like other contract manufacturers such as Lonza, is betting the next big wave of demand will be for complex production of gene therapies and other products such as viral vaccines and immunotherapies. The gene therapy market will grow to about $10 billion by 2026 from $1 billion in 2018, the company said, citing estimates from Biotech Forecasts.

"Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals," said Udit Batra, head of Merck KGaA'slife science business, in a statement.

The German company has been on a spending spree in recent years, announcing plans to invest 1 billion euros in its global headquarters in Darmstadt, more than $400 million in two sites in Switzerland,and $70 million in a research and development hub expansion in Billerica, Massachusetts.

Carlsbad is already home to a Merck KGaA facility that has been involved in gene therapy since 1997, about the time that researchers beginning studying the potential for such treatments in people. At present, the site has 16 modular viral bulk manufacturing clean room suites and two fill/finish suites, Merck KGaA said.

With the new facility, the Carlsbad location will have 27 suites used in different parts of the manufacturing process and will support production at the 1000-liter scale using single-use equipment, Merck KGaA said.

The company also has a manufacturing facility in Glasgow that produces intermediates and final products for gene therapy and viral vaccines.

Merck KGaA, established in 1688, is majority owned by descendants of the original founder and had sales of 16.2 billion euros last year. The U.S. pharmaceutical giant Merck was once a subsidiary but is no longer associated with its German namesake.

View post:
Merck KGaA to spend $110M on new gene therapy facility in California - BioPharma Dive

Recommendation and review posted by Bethany Smith

SAN RAFAEL, Calif., April29, 2020 /PRNewswire/ --

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)

Three Months Ended March 31,

2020

2019

% Change

Total Revenues

$

502.1

$

400.7

25

%

Net Product Revenues Marketed by BioMarin (1)

433.3

349.2

24

%

Vimizim Net Product Revenues

137.2

125.8

9

%

Kuvan Net Product Revenues

122.0

106.9

14

%

Naglazyme Net Product Revenues

114.3

86.9

32

%

Palynziq Net Product Revenues

34.6

12.3

181

%

Brineura Net Product Revenues

24.0

12.2

97

%

Aldurazyme Net Product Revenues

55.7

45.3

23

%

GAAP Net Income (Loss)

$

81.4

$

(56.5)

GAAP Net Income (Loss) per Share Basic

$

0.45

$

(0.32)

GAAP Net Income (Loss) per Share Diluted

$

0.44

$

(0.32)

Non-GAAP Income(2)

$

116.5

$

24.8

March 31,

2020

December 31,

2019

Cash, cash equivalents and investments

$

1,149.2

$

1,165.8

(1)

Net Product Revenues Marketed by BioMarin is the sum of revenues from Vimizim, Kuvan, Naglazyme, Palynziq, Brineura and Firdapse, each calculated in accordance with Generally Accepted Accounting Principles in the United States (U.S. GAAP). Sanofi Genzyme (Genzyme) is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties. Refer to page9 for a table showing Net Product Revenues by product, including Firdapse. In January 2020, BioMarin divested the Firdapse assets to a third party in a sale transaction. The sale will be reflected in the Company's consolidated financial statements for the three months ending March 31, 2020; as a result of the transaction BioMarin will not recognize Net Product Revenues from Firdapse in the future.

(2)

Non-GAAP Income is defined by the Company as reported GAAP Net Income, excluding net interest expense, provision for (benefit from) income taxes, depreciation expense, amortization expense, stock-based compensation expense, contingent consideration expense and, in certain periods, certain other specified items. Refer to Non-GAAP Information beginning on page10 of this press release for a complete discussion of the Company's Non-GAAP financial information and reconciliations to the comparable information reported under U.S. GAAP.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (BioMarin or the Company) today announced financial results for the first quarter ended March31, 2020.

Total Revenues increased 25% to $502.1 million. The increase in Total Revenues was primarily attributed to increased Net Product Revenues which were $489.0 million in the first quarter of 2020, compared to $394.5 million for the first quarter of 2019. The increase in Net Product Revenues was attributed to the following:

The increase in GAAP Net Income for the first quarter of 2020, compared to GAAP Net Loss for the same period in 2019 was primarily due to the following:

Non-GAAP Income for the first quarter of 2020 increased to $116.5 million, compared to Non-GAAP Income of $24.8 million for the same period in 2019. The increase in Non-GAAP Income for the quarter, compared to the same period in 2019, was attributed to higher gross profit and decreased R&D expense, partially offset by higher SG&A expense.

As of March31, 2020, BioMarin had cash, cash equivalents and investments totaling approximately $1.1 billion, as compared to $1.2 billion on December31, 2019.

Commenting on first quarter 2020 results, Jean-Jacques Bienaim, Chairman and Chief Executive Officer of BioMarin, said, "With the arrival of COVID-19 to the many regions where we do business, BioMarin employees performed in unprecedented ways to ensure the continued supply of our critically-important medicines to the people we serve. I am proud of the commitment and dedication demonstrated by our colleagues in these challenging times. Our strong financial results in the first quarter underscore both the essential-nature of our products to patients and the extraordinary efforts made to maintain supply around the world. In the face of the many challenges of COVID-19, our regulatory team further progressed our next two potential commercial products. The Biologics License Application (BLA) for valoctocogene roxaparvovec for severe hemophilia A was accepted for Priority Review from the FDA with an action date of August 21, 2020. This milestone represents a tremendous achievement for BioMarin, but the potential approval of the first gene therapy in any type of hemophilia is an even greater triumph for the hemophilia community. They have been waiting decades for this groundbreaking advancement and we are honored to be on this journey together. With an approval decision for valoctocogene roxaparvovec expected later this year, our commercial team prepares eagerly to launch what we believe is the most innovative product yet for people with bleeding disorders."

Mr. Bienaim continued, "Based on positive interactions with U.S. and European regulatory authorities in the quarter, we plan to submit marketing applications in both regions for vosoritide to treat children with achondroplasia in the third quarter of this year. Our multi-pronged dossier of data encompasses long-term clinical results in 5 to 18 year-olds, natural history data, the ongoing study of newborns through 5 years, and highly statistically significant placebo-controlled Phase 3 results. The positive and significant results from our vosoritide clinical programs have led us to believe that this potential drug could be the first pharmacological treatment for the underlying cause of achondroplasia. Interest in our clinical studies with vosoritide has been extremely robust, demonstrating that families are keen to seek early treatment for their children."

Mr. Bienaim concluded, "2020 is expected to be a transformational year for BioMarin, despite impact from COVID-19 in the near-term. The agility demonstrated by BioMarin employees in the face of this global pandemic has enabled the continued supply of our essential medicines to the patients who need them. And while we expect minor financial impact in the near-term, our business is well-positioned to weather such challenges. Our first quarter revenue growth and improvement in profitability support our belief that 2020 continues to look poised to be one of our most significant value-creating years to date."

2020 Full-Year Financial Guidance

Due to the uncertainty surrounding the COVID-19 pandemic and the potential impact on its business, BioMarin is reducing its guidance for Total Revenues and Net Product Revenues for Vimizim, Naglazyme and Palynziq for 2020.

Item

Provided February 26, 2020

Updated April 29, 2020

Total Revenues (1)

$1,950

to

$2,050

$1,850

to

Read more from the original source:
BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million - PRNewswire

Recommendation and review posted by Bethany Smith

What are exosomes?

Exosomes are a class of cell-derived extracellular vesicles of endosomal origin, and are typically 30-150 nm in diameter the smallest type of extracellular vesicle.1 Enveloped by a lipid bilayer, exosomes are released into the extracellular environment containing a complex cargo of contents derived from the original cell, including proteins, lipids, mRNA, miRNA and DNA.2 Exosomes are defined by how they are formed through the fusion and exocytosis of multivesicular bodies into the extracellular space.

Multivesicular bodies* are unique organelles in the endocytic pathway that function as intermediates between early and late endosomes.3 The main function of multivesicular bodies is to separate components that will be recycled elsewhere from those that will be degraded by lysosomes.4 The vesicles that accumulate within multivesicular bodies are categorized as intraluminal vesicles while inside the cytoplasm and exosomes when released from the cell.

*Confusingly, there is inconsistency in the literature; while some sources differentiate multivesicular bodies from late endosomes, others use the two interchangeably.

Exosomes are of general interest for their role in cell biology, and for their potential therapeutic and diagnostic applications. It was originally thought that exosomes were simply cellular waste products, however their function is now known to extend beyond waste removal. Exosomes represent a novel mode of cell communication and contribute to a spectrum of biological processes in health and disease.2One of the main mechanisms by which exosomes are thought to exert their effects is via the transfer of exosome-associated RNA to recipient cells, where they influence protein machinery. There is growing evidence to support this, such as the identification of intact and functional exosomal RNA in recipient cells and certain RNA-binding proteins have been identified as likely players in the transfer of RNA to target cells.5,6 MicroRNAs and long noncoding RNAs are shuttled by exosomes and alter gene expression while proteins (e.g. heat shock proteins, cytoskeletal proteins, adhesion molecules, membrane transporter and fusion proteins) can directly affect target cells.7,8Exosomes have been described as messengers of both health and disease. While they are essential for normal physiological conditions, they also act to potentiate cellular stress and damage under disease states.2

Multivesicular bodies are a specialized subset of endosomes that contain membrane-bound intraluminal vesicles. Intraluminal vesicles are essentially the precursors of exosomes, and form by budding into the lumen of the multivesicular body. Most intraluminal vesicles fuse with lysosomes for subsequent degradation, while others are released into the extracellular space.9,10 The intraluminal vesicles that are secreted into the extracellular space become exosomes. This release occurs when the multivesicular body fuses with the plasma membrane.

The formation and degradation of exosomes.

This is an active area of research and it is not yet known how exosome release is regulated. However, recent advances in imaging protocols may allow exosome release events to be visualized at high spatiotemporal resolution.11

Exosomes have been implicated in a diverse range of conditions including neurodegenerative diseases, cancer, liver disease and heart failure. Like other microvesicles, the function of exosomes likely depends on the cargo they carry, which is dependent on the cell type in which they were produced.12 Researchers have studied exosomes in disease through a range of approaches, including:

In cancer, exosomes have multiple roles in metastatic spread, drug resistance and angiogenesis. Specifically, exosomes can alter the extracellular matrix to create space for migrating tumor cells.13,14 Several studies also indicate that exosomes can increase the migration, invasion and secretion of cancer cells by influencing genes involved with tumor suppression and extracellular matrix degradation.15,16Through general cell crosstalk, exosomal miRNA and lncRNA affect the progression of lung diseases including chronic obstructive pulmonary disease (COPD), asthma, tuberculosis and interstitial lung diseases. Stressors such as oxidant exposure can influence the secretion and cargo of exosomes, which in turn affect inflammatory reactions.17 Altered exosomal profiles in diseased states also imply a role for exosomes in many other conditions such as in neurodegenerative diseases and mental disorders.18,19Cells exposed to bacteria release exosomes which act like decoys to toxins, suggesting a protective effect during infection.20 In neuronal circuit development, and in many other systems, exosomal signaling is likely to be a sum of overlapping and sometimes opposing signaling networks.21

Exosomes can function as potential biomarkers, as their contents are molecular signatures of their originating cells. Due to the lipid bilayer, exosomal contents are relatively stable and protected against external proteases and other enzymes, making them attractive diagnostic tools. There are increasing reports that profiles of exosomal miRNA and lncRNA differ in patients with certain pathologies, compared with those of healthy people.17 Consequently, exosome-based diagnostic tests are being pursued for the early detection of cancer, diabetes and other diseases.22,23Many exosomal proteins, nucleic acids and lipids are being explored as potential clinically relevant biomarkers.24 Phosphorylation proteins are promising biomarkers that can be separated from exosomal samples even after five years in the freezer25, while exosomal microRNA also appears to be highly stable.26 Exosomes are also highly accessible as they are present in a wide array of biofluids (including blood, urine, saliva, tears, ascites, semen, colostrum, breast milk, amniotic fluid and cerebrospinal fluid), creating many opportunities for liquid biopsies.

Exosomes are being pursued for use in an array of potential therapeutic applications. While externally modified vesicles suffer from toxicity and rapid clearance, membranes of naturally occurring vesicles are better tolerated, offering low immunogenicity and a high resilience in extracellular fluid.27 These naturally-equipped nanovesicles could be therapeutically targeted or engineered as drug delivery systems.

Exosomes bear surface molecules that allow them to be targeted to recipient cells, where they deliver their payload. This could be used to target them to diseased tissues or organs.27 Exosomes may cross the blood-brain barrier, at least under certain conditions28 and could be used to deliver an array of therapies including small molecules, RNA therapies, proteins, viral gene therapy and CRISPR gene-editing.

Different approaches to creating drug-loaded exosomes include27:

Exosomes hold huge potential as a way to complement chimeric antigen receptor T (CAR-T) cells in attacking cancer cells. CAR exosomes, which are released from CAR-T cells, carry CAR on their surface and express a high level of cytotoxic molecules and inhibit tumor growth.29 Cancer cell-derived exosomes carrying associated antigens have also been shown to recruit an antitumor immune response.30

The purification of exosomes is a key challenge in the development of translational tools. Exosomes must be differentiated from other distinct populations of extracellular vesicles, such as microvesicles (which shed from the plasma membrane, also referred to as ectosomes or shedding vesicles) and apoptotic bodies.31 Although ultracentrifugation is regarded as the gold standard for exosome isolation, it has many disadvantages and alternative methods for exosome isolation are currently being sought. Exosome isolation is an active area of research (see Table 1) and many research groups are seeking ways to overcome the disadvantages listed below, while navigating the relevant regulatory hurdles along the way.

Produces a low yield and low purity of the isolated exosomes as other types of extracellular vesicles have similar sedimentation properties.

Low efficiency as it is labor-intensive, time-consuming and requires a large amount of sample. specialized equipment. High centrifugal force can damage exosome integrity

Originally posted here:
Exosomes: Definition, Function and Use in Therapy - Technology Networks

Recommendation and review posted by Bethany Smith

The Personalized Gene Therapy Treatment Market report market intelligence study intended to offer complete understanding of global market scenario with the Impact of COVID-19 (Corona Virus). It attempts to analyze the major components of the Market which have greater influence on it. This includes various elements of significant nature including market overview, segmentation, competition landscape, Market chain analysis, key players stratergyand more. Also, the report provides a 360-degree overview of global market on the basis of various analysis techniques including SWOT and Porters Five Forces. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. This might help readers to understand the strengths, opportunities, challenges and perceived threats of the market.

Based on Classification, each type is studied as Sales, Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information. The report can help to realize the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Personalized Gene Therapy Treatment industry.

The Personalized Gene Therapy Treatment Market report wraps:

There are 13 Chapters to thoroughly display the Personalized Gene Therapy Treatment market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

In the end, The objective of the market research report is the current status of the market and in accordance classifies it into a few objects. The report takes into consideration the first market players in every area from over the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Read the rest here:
Personalized Gene Therapy Treatment Market: What are the Future Growth Opportunities with Covid-19? - Cole of Duty

Recommendation and review posted by Bethany Smith

The Gene Therapy For Rare Disease Market report market intelligence study intended to offer complete understanding of global market scenario with the Impact of COVID-19 (Corona Virus). It attempts to analyze the major components of the Market which have greater influence on it. This includes various elements of significant nature including market overview, segmentation, competition landscape, Market chain analysis, key players stratergyand more. Also, the report provides a 360-degree overview of global market on the basis of various analysis techniques including SWOT and Porters Five Forces. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. This might help readers to understand the strengths, opportunities, challenges and perceived threats of the market.

Based on Classification, each type is studied as Sales, Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information. The report can help to realize the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Gene Therapy For Rare Disease industry.

The Gene Therapy For Rare Disease Market report wraps:

There are 13 Chapters to thoroughly display the Gene Therapy For Rare Disease market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

In the end, The objective of the market research report is the current status of the market and in accordance classifies it into a few objects. The report takes into consideration the first market players in every area from over the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Continue reading here:
Gene Therapy For Rare Disease Market | Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 - Cole of...

Recommendation and review posted by Bethany Smith

Increasing number of new drug launches, rise in chronic disease burden, and increasing government support for the pharmaceutical and biotechnology industries will also aid the growth of this market.

Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics. The major drivers for the market are rapid growth in pharmaceutical and biotechnology industries and strong trend of R&D investments in life sciences industry.

The global viral inactivation market poised to grow at a CAGR of 12.3%, to reach USD 573.0 Million.

Viral inactivation is important and mandatory step in the manufacturing process of biological products to remove or inactivate potential contaminant viruses. These biological products are used for the treatment and diagnostic purposes in humans.

As the disease burden in the world is increasing the demand for the medicines is increasing hence the production of biologicals, injectables., is on a rise. many of pharmaceutical and biotechnology firms are gearing to cater to the growing demands of medicines.

This aids to the growth of market.

Download PDF Brochure:www.marketsandmarkets.com/pdfdown=121427017

The globalviral inactivation market is segmented based on method, product, application, end user, and geography.

Market Segmentation in depth:

Based on end user this market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users. Other end user segment primarily includes cell banks, small cell culture laboratories and consultants, microbiology laboratories, immunology laboratories, molecular laboratories, animal facilities, toxicology laboratories, and media/sera manufacturers.

The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics. Based on geography the market is segmented into North America, Europe, Asia and Rest of the World (RoW).

Report: http://www.marketsandmarkets.com/request=121427017

Based on geography the viral inactivation market is segmented into North America, Europe, Asia and Rest of the World (RoW).

The major players in theViral Inactivation Marketinclude Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A.

(Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).

This email address is being protected from spambots. You need JavaScript enabled to view it.

Original post:
Viral Inactivation Market estimated to grow according to forecasts - WhaTech Technology and Markets News

Recommendation and review posted by Bethany Smith

The research study presented here is an intelligent take on the global Human Interleukin-2 (IL-2) Market that explains important aspects such as competition, segmentation, and regional growth in great detail. Accuracy and preciseness are two of the key features of the report that reflect its authenticity. The authors of the report have focused on SWOT analysis, Porters Five Forces analysis, and PESTLE analysis of the global Human Interleukin-2 (IL-2) market. In addition, they have concentrated on qualitative and quantitative analyses to help with a deep understanding of the global Human Interleukin-2 (IL-2) market. Furthermore, the report provides powerful suggestions and recommendations to help players create strong growth strategies and ensure impressive sales in the global Human Interleukin-2 (IL-2) market.

Some of the influential Key Player operated in the report are: Roche BMS Schering-Plough AbbVie Inc Alkermes Plc APT Therapeutics Mabtech Limited Philogen Sinopharm Jiangsu Jinsili Pharmaceutical Shenyang Sansheng Pharmaceutical Beijing Shuanglu Pharmaceutical Shandong Quangang Pharmaceutical Shanghai Huaxin Biological high-tech Beijing Yuance Pharmaceutical Beijing Sihuan Biological Pharmaceutical Beijing Sanyuan Gene Pharmaceutical Shenzhen Kexing Biological Engineering Shanghai Sanwei Biotechnology Xiamen Tebao Biological Engineering Chengdu huashen Biotechnology Shanghai Pharma Group Guangdong Xinghao Pharmaceutical Market Segment by Type 50000 U 100000 U 200000 U 500000 U 1 Million U 2 Million U Market Segment by Application Recombinant Interferon Recombinant Interleukin Natural Biological Products Poison Immune Gene Therapy Monoclonal Antibody Research Methodology To compile the detailed study of the global Human Interleukin-2 (IL-2) market, a robust research methodology has been adopted that aids in determining the key insights and also evaluates the growth prospects of the Human Interleukin-2 (IL-2) market. QY Research analysts have conducted in-depth primary and secondary research to obtain crucial insights into the Human Interleukin-2 (IL-2) market. To carry out secondary research, the analysts have collected the information through company annual reports, journals, company press releases, and paid databases that were referred to gain and identify better opportunities in the global market.

Get PDF Sample Copy of this Report including (Product, Summary, TOC, TOF, Industry analysis): https://www.qyresearch.com/sample-form/form/1540624/global-human-interleukin-2-il-2-industry

As part of competitive analysis, the research study includes exhaustive company profiling of leading players of the global Human Interleukin-2 (IL-2) market. All of the segments studied in the report are analyzed based on different factors such as market share, revenue, and CAGR. The analysts have also thoroughly analyzed different regions such as North America, Europe, and the Asia Pacific on the basis of production, revenue, and sales in the global Human Interleukin-2 (IL-2) market. The researchers used advanced primary and secondary research methodologies and tools for preparing this report on the global Human Interleukin-2 (IL-2) market.

Segmentation by Type:

50000 U, 100000 U, 200000 U, 500000 U, 1 Million U, 2 Million U Market

Segmentation by Application:

Recombinant Interferon, Recombinant Interleukin, Natural Biological Products, Poison Immune, Gene Therapy, Monoclonal Antibody Research Methodology To compile the detailed study of the

Table of Contents

Table of Contents1 Report Overview1.1 Research Scope1.2 Top Human Interleukin-2 (IL-2) Manufacturers Covered: Ranking by Revenue1.3 Market Segment by Type1.3.1 Global Human Interleukin-2 (IL-2) Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)1.3.2 50000 U1.3.3 100000 U1.3.4 200000 U1.3.5 500000 U1.3.6 1 Million U1.3.7 2 Million U1.4 Market Segment by Application1.4.1 Global Human Interleukin-2 (IL-2) Consumption by Application: 2015 VS 2020 VS 20261.4.2 Recombinant Interferon1.4.3 Recombinant Interleukin1.4.4 Natural Biological Products1.4.5 Poison Immune1.4.6 Gene Therapy1.4.7 Monoclonal Antibody1.5 Study Objectives1.6 Years Considered 2 Global Market Perspective2.1 Global Human Interleukin-2 (IL-2) Revenue (2015-2026)2.1.1 Global Human Interleukin-2 (IL-2) Revenue (2015-2026)2.1.2 Global Human Interleukin-2 (IL-2) Sales (2015-2026)2.2 Human Interleukin-2 (IL-2) Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 20262.2.1 Global Human Interleukin-2 (IL-2) Sales by Regions (2015-2020)2.2.2 Global Human Interleukin-2 (IL-2) Revenue by Regions (2015-2020)2.3 Global Top Human Interleukin-2 (IL-2) Regions (Countries) Ranking by Market Size2.4 Human Interleukin-2 (IL-2) Industry Trends2.4.1 Human Interleukin-2 (IL-2) Market Top Trends2.4.2 Market Drivers2.4.3 Human Interleukin-2 (IL-2) Market Challenges2.4.4 Porters Five Forces Analysis2.4.5 Primary Interviews with Key Human Interleukin-2 (IL-2) Players: Views for Future3 Competitive Landscape by Manufacturers3.1 Global Top Human Interleukin-2 (IL-2) Manufacturers by Sales (2015-2020)3.1.1 Global Human Interleukin-2 (IL-2) Sales by Manufacturers (2015-2020)3.1.2 Global Human Interleukin-2 (IL-2) Sales Market Share by Manufacturers (2015-2020)3.1.3 Global 5 and 10 Largest Manufacturers by Human Interleukin-2 (IL-2) Sales in 20193.2 Global Top Manufacturers Human Interleukin-2 (IL-2) by Revenue3.2.1 Global Human Interleukin-2 (IL-2) Revenue by Manufacturers (2015-2020)3.2.2 Global Human Interleukin-2 (IL-2) Revenue Share by Manufacturers (2015-2020)3.2.3 Global Human Interleukin-2 (IL-2) Market Concentration Ratio (CR5 and HHI)3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Interleukin-2 (IL-2) as of 2019)3.4 Global Human Interleukin-2 (IL-2) Average Selling Price (ASP) by Manufacturers3.5 Key Manufacturers Human Interleukin-2 (IL-2) Plants/Factories Distribution and Area Served3.6 Date of Key Manufacturers Enter into Human Interleukin-2 (IL-2) Market3.7 Key Manufacturers Human Interleukin-2 (IL-2) Product Offered3.8 Mergers & Acquisitions, Expansion Plans4 Market Size by Type4.1 Global Human Interleukin-2 (IL-2) Historic Market Review by Type (2015-2020)4.1.2 Global Human Interleukin-2 (IL-2) Sales Market Share by Type (2015-2020)4.1.3 Global Human Interleukin-2 (IL-2) Revenue Market Share by Type (2015-2020)4.1.4 Human Interleukin-2 (IL-2) Price by Type (2015-2020)4.1 Global Human Interleukin-2 (IL-2) Market Estimates and Forecasts by Type (2021-2026)4.2.2 Global Human Interleukin-2 (IL-2) Sales Forecast by Type (2021-2026)4.2.3 Global Human Interleukin-2 (IL-2) Revenue Forecast by Type (2021-2026)4.2.4 Human Interleukin-2 (IL-2) Price Forecast by Type (2021-2026)5 Global Human Interleukin-2 (IL-2) Market Size by Application5.1 Global Human Interleukin-2 (IL-2) Historic Market Review by Application (2015-2020)5.1.2 Global Human Interleukin-2 (IL-2) Sales Market Share by Application (2015-2020)5.1.3 Global Human Interleukin-2 (IL-2) Revenue Market Share by Application (2015-2020)5.1.4 Human Interleukin-2 (IL-2) Price by Application (2015-2020)5.2 Global Human Interleukin-2 (IL-2) Market Estimates and Forecasts by Application (2021-2026)5.2.2 Global Human Interleukin-2 (IL-2) Sales Forecast by Application (2021-2026)5.2.3 Global Human Interleukin-2 (IL-2) Revenue Forecast by Application (2021-2026)5.2.4 Human Interleukin-2 (IL-2) Price Forecast by Application (2021-2026)6 North America6.1 North America Human Interleukin-2 (IL-2) Breakdown Data by Company6.2 North America Human Interleukin-2 (IL-2) Breakdown Data by Type6.3 North America Human Interleukin-2 (IL-2) Breakdown Data by Application6.4 North America Human Interleukin-2 (IL-2) Breakdown Data by Countries6.4.1 North America Human Interleukin-2 (IL-2) Sales by Countries6.4.2 North America Human Interleukin-2 (IL-2) Revenue by Countries6.4.3 U.S.6.4.4 Canada7 Europe7.1 Europe Human Interleukin-2 (IL-2) Breakdown Data by Company7.2 Europe Human Interleukin-2 (IL-2) Breakdown Data by Type7.3 Europe Human Interleukin-2 (IL-2) Breakdown Data by Application7.4 Europe Human Interleukin-2 (IL-2) Breakdown Data by Countries7.4.1 Europe Human Interleukin-2 (IL-2) Sales by Countries7.4.2 Europe Human Interleukin-2 (IL-2) Revenue by Countries7.4.3 Germany7.4.4 France7.4.5 U.K.7.4.6 Italy7.4.7 Russia8 Asia Pacific8.1 Asia Pacific Human Interleukin-2 (IL-2) Breakdown Data by Company8.2 Asia Pacific Human Interleukin-2 (IL-2) Breakdown Data by Type8.3 Asia Pacific Human Interleukin-2 (IL-2) Breakdown Data by Application8.4 Asia Pacific Human Interleukin-2 (IL-2) Breakdown Data by Regions8.4.1 Asia Pacific Human Interleukin-2 (IL-2) Sales by Regions8.4.2 Asia Pacific Human Interleukin-2 (IL-2) Revenue by Regions8.4.3 China8.4.4 Japan8.4.5 South Korea8.4.6 India8.4.7 Australia8.4.8 Taiwan8.4.9 Indonesia8.4.10 Thailand8.4.11 Malaysia8.4.12 Philippines8.4.13 Vietnam9 Latin America9.1 Latin America Human Interleukin-2 (IL-2) Breakdown Data by Company9.2 Latin America Human Interleukin-2 (IL-2) Breakdown Data by Type9.3 Latin America Human Interleukin-2 (IL-2) Breakdown Data by Application9.4 Latin America Human Interleukin-2 (IL-2) Breakdown Data by Countries9.4.1 Latin America Human Interleukin-2 (IL-2) Sales by Countries9.4.2 Latin America Human Interleukin-2 (IL-2) Revenue by Countries9.4.3 Mexico9.4.4 Brazil9.4.5 Argentina10 Middle East and Africa10.1 Middle East and Africa Human Interleukin-2 (IL-2) Breakdown Data by Type10.2 Middle East and Africa Human Interleukin-2 (IL-2) Breakdown Data by Application10.3 Middle East and Africa Human Interleukin-2 (IL-2) Breakdown Data by Countries10.3.1 Middle East and Africa Human Interleukin-2 (IL-2) Sales by Countries10.3.2 Middle East and Africa Human Interleukin-2 (IL-2) Revenue by Countries10.3.3 Turkey10.3.4 Saudi Arabia10.3.5 U.A.E11 Company Profiles11.1 Roche11.1.1 Roche Corporation Information11.1.2 Roche Business Overview and Total Revenue (2019 VS 2018)11.1.3 Roche Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.1.4 Roche Human Interleukin-2 (IL-2) Products and Services11.1.5 Roche SWOT Analysis11.1.6 Roche Recent Developments11.2 BMS11.2.1 BMS Corporation Information11.2.2 BMS Business Overview and Total Revenue (2019 VS 2018)11.2.3 BMS Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.2.4 BMS Human Interleukin-2 (IL-2) Products and Services11.2.5 BMS SWOT Analysis11.2.6 BMS Recent Developments11.3 Schering-Plough11.3.1 Schering-Plough Corporation Information11.3.2 Schering-Plough Business Overview and Total Revenue (2019 VS 2018)11.3.3 Schering-Plough Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.3.4 Schering-Plough Human Interleukin-2 (IL-2) Products and Services11.3.5 Schering-Plough SWOT Analysis11.3.6 Schering-Plough Recent Developments11.4 AbbVie Inc11.4.1 AbbVie Inc Corporation Information11.4.2 AbbVie Inc Business Overview and Total Revenue (2019 VS 2018)11.4.3 AbbVie Inc Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.4.4 AbbVie Inc Human Interleukin-2 (IL-2) Products and Services11.4.5 AbbVie Inc SWOT Analysis11.4.6 AbbVie Inc Recent Developments11.5 Alkermes Plc11.5.1 Alkermes Plc Corporation Information11.5.2 Alkermes Plc Business Overview and Total Revenue (2019 VS 2018)11.5.3 Alkermes Plc Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.5.4 Alkermes Plc Human Interleukin-2 (IL-2) Products and Services11.5.5 Alkermes Plc SWOT Analysis11.5.6 Alkermes Plc Recent Developments11.6 APT Therapeutics11.6.1 APT Therapeutics Corporation Information11.6.2 APT Therapeutics Business Overview and Total Revenue (2019 VS 2018)11.6.3 APT Therapeutics Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.6.4 APT Therapeutics Human Interleukin-2 (IL-2) Products and Services11.6.5 APT Therapeutics SWOT Analysis11.6.6 APT Therapeutics Recent Developments11.7 Mabtech Limited11.7.1 Mabtech Limited Corporation Information11.7.2 Mabtech Limited Business Overview and Total Revenue (2019 VS 2018)11.7.3 Mabtech Limited Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.7.4 Mabtech Limited Human Interleukin-2 (IL-2) Products and Services11.7.5 Mabtech Limited SWOT Analysis11.7.6 Mabtech Limited Recent Developments11.8 Philogen11.8.1 Philogen Corporation Information11.8.2 Philogen Business Overview and Total Revenue (2019 VS 2018)11.8.3 Philogen Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.8.4 Philogen Human Interleukin-2 (IL-2) Products and Services11.8.5 Philogen SWOT Analysis11.8.6 Philogen Recent Developments11.9 Sinopharm11.9.1 Sinopharm Corporation Information11.9.2 Sinopharm Business Overview and Total Revenue (2019 VS 2018)11.9.3 Sinopharm Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.9.4 Sinopharm Human Interleukin-2 (IL-2) Products and Services11.9.5 Sinopharm SWOT Analysis11.9.6 Sinopharm Recent Developments11.10 Jiangsu Jinsili Pharmaceutical11.10.1 Jiangsu Jinsili Pharmaceutical Corporation Information11.10.2 Jiangsu Jinsili Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)11.10.3 Jiangsu Jinsili Pharmaceutical Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.10.4 Jiangsu Jinsili Pharmaceutical Human Interleukin-2 (IL-2) Products and Services11.10.5 Jiangsu Jinsili Pharmaceutical SWOT Analysis11.10.6 Jiangsu Jinsili Pharmaceutical Recent Developments11.11 Shenyang Sansheng Pharmaceutical11.11.1 Shenyang Sansheng Pharmaceutical Corporation Information11.11.2 Shenyang Sansheng Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)11.11.3 Shenyang Sansheng Pharmaceutical Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.11.4 Shenyang Sansheng Pharmaceutical Human Interleukin-2 (IL-2) Products and Services11.11.5 Shenyang Sansheng Pharmaceutical SWOT Analysis11.11.6 Shenyang Sansheng Pharmaceutical Recent Developments11.12 Beijing Shuanglu Pharmaceutical11.12.1 Beijing Shuanglu Pharmaceutical Corporation Information11.12.2 Beijing Shuanglu Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)11.12.3 Beijing Shuanglu Pharmaceutical Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.12.4 Beijing Shuanglu Pharmaceutical Human Interleukin-2 (IL-2) Products and Services11.12.5 Beijing Shuanglu Pharmaceutical SWOT Analysis11.12.6 Beijing Shuanglu Pharmaceutical Recent Developments11.13 Shandong Quangang Pharmaceutical11.13.1 Shandong Quangang Pharmaceutical Corporation Information11.13.2 Shandong Quangang Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)11.13.3 Shandong Quangang Pharmaceutical Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.13.4 Shandong Quangang Pharmaceutical Human Interleukin-2 (IL-2) Products and Services11.13.5 Shandong Quangang Pharmaceutical SWOT Analysis11.13.6 Shandong Quangang Pharmaceutical Recent Developments11.14 Shanghai Huaxin Biological high-tech11.14.1 Shanghai Huaxin Biological high-tech Corporation Information11.14.2 Shanghai Huaxin Biological high-tech Business Overview and Total Revenue (2019 VS 2018)11.14.3 Shanghai Huaxin Biological high-tech Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.14.4 Shanghai Huaxin Biological high-tech Human Interleukin-2 (IL-2) Products and Services11.14.5 Shanghai Huaxin Biological high-tech SWOT Analysis11.14.6 Shanghai Huaxin Biological high-tech Recent Developments11.15 Beijing Yuance Pharmaceutical11.15.1 Beijing Yuance Pharmaceutical Corporation Information11.15.2 Beijing Yuance Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)11.15.3 Beijing Yuance Pharmaceutical Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.15.4 Beijing Yuance Pharmaceutical Human Interleukin-2 (IL-2) Products and Services11.15.5 Beijing Yuance Pharmaceutical SWOT Analysis11.15.6 Beijing Yuance Pharmaceutical Recent Developments11.16 Beijing Sihuan Biological Pharmaceutical11.16.1 Beijing Sihuan Biological Pharmaceutical Corporation Information11.16.2 Beijing Sihuan Biological Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)11.16.3 Beijing Sihuan Biological Pharmaceutical Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.16.4 Beijing Sihuan Biological Pharmaceutical Human Interleukin-2 (IL-2) Products and Services11.16.5 Beijing Sihuan Biological Pharmaceutical SWOT Analysis11.16.6 Beijing Sihuan Biological Pharmaceutical Recent Developments11.17 Beijing Sanyuan Gene Pharmaceutical11.17.1 Beijing Sanyuan Gene Pharmaceutical Corporation Information11.17.2 Beijing Sanyuan Gene Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)11.17.3 Beijing Sanyuan Gene Pharmaceutical Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.17.4 Beijing Sanyuan Gene Pharmaceutical Human Interleukin-2 (IL-2) Products and Services11.17.5 Beijing Sanyuan Gene Pharmaceutical SWOT Analysis11.17.6 Beijing Sanyuan Gene Pharmaceutical Recent Developments11.18 Shenzhen Kexing Biological Engineering11.18.1 Shenzhen Kexing Biological Engineering Corporation Information11.18.2 Shenzhen Kexing Biological Engineering Business Overview and Total Revenue (2019 VS 2018)11.18.3 Shenzhen Kexing Biological Engineering Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.18.4 Shenzhen Kexing Biological Engineering Human Interleukin-2 (IL-2) Products and Services11.18.5 Shenzhen Kexing Biological Engineering SWOT Analysis11.18.6 Shenzhen Kexing Biological Engineering Recent Developments11.19 Shanghai Sanwei Biotechnology11.19.1 Shanghai Sanwei Biotechnology Corporation Information11.19.2 Shanghai Sanwei Biotechnology Business Overview and Total Revenue (2019 VS 2018)11.19.3 Shanghai Sanwei Biotechnology Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.19.4 Shanghai Sanwei Biotechnology Human Interleukin-2 (IL-2) Products and Services11.19.5 Shanghai Sanwei Biotechnology SWOT Analysis11.19.6 Shanghai Sanwei Biotechnology Recent Developments11.20 Xiamen Tebao Biological Engineering11.20.1 Xiamen Tebao Biological Engineering Corporation Information11.20.2 Xiamen Tebao Biological Engineering Business Overview and Total Revenue (2019 VS 2018)11.20.3 Xiamen Tebao Biological Engineering Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.20.4 Xiamen Tebao Biological Engineering Human Interleukin-2 (IL-2) Products and Services11.20.5 Xiamen Tebao Biological Engineering SWOT Analysis11.20.6 Xiamen Tebao Biological Engineering Recent Developments11.21 Chengdu huashen Biotechnology11.21.1 Chengdu huashen Biotechnology Corporation Information11.21.2 Chengdu huashen Biotechnology Business Overview and Total Revenue (2019 VS 2018)11.21.3 Chengdu huashen Biotechnology Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.21.4 Chengdu huashen Biotechnology Human Interleukin-2 (IL-2) Products and Services11.21.5 Chengdu huashen Biotechnology SWOT Analysis11.21.6 Chengdu huashen Biotechnology Recent Developments11.22 Shanghai Pharma Group11.22.1 Shanghai Pharma Group Corporation Information11.22.2 Shanghai Pharma Group Business Overview and Total Revenue (2019 VS 2018)11.22.3 Shanghai Pharma Group Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.22.4 Shanghai Pharma Group Human Interleukin-2 (IL-2) Products and Services11.22.5 Shanghai Pharma Group SWOT Analysis11.22.6 Shanghai Pharma Group Recent Developments11.23 Guangdong Xinghao Pharmaceutical11.23.1 Guangdong Xinghao Pharmaceutical Corporation Information11.23.2 Guangdong Xinghao Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)11.23.3 Guangdong Xinghao Pharmaceutical Human Interleukin-2 (IL-2) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.23.4 Guangdong Xinghao Pharmaceutical Human Interleukin-2 (IL-2) Products and Services11.23.5 Guangdong Xinghao Pharmaceutical SWOT Analysis11.23.6 Guangdong Xinghao Pharmaceutical Recent Developments12 Supply Chain and Sales Channels Analysis12.1 Supply Chain Analysis12.2 Sales Channels Analysis12.2.1 Human Interleukin-2 (IL-2) Sales Channels12.2.2 Human Interleukin-2 (IL-2) Distributors12.3 Human Interleukin-2 (IL-2) Customers13 Estimates and Projections by Regions (2021-2026)13.1 Global Human Interleukin-2 (IL-2) Sales Forecast (2021-2026)13.1.1 Global Human Interleukin-2 (IL-2) Sales Forecast by Regions (2021-2026)13.1.2 Global Human Interleukin-2 (IL-2) Revenue Forecast by Regions (2021-2026)13.2 North America Market Size Forecast (2021-2026)13.2.1 North America Human Interleukin-2 (IL-2) Sales Forecast (2021-2026)13.2.2 North America Human Interleukin-2 (IL-2) Revenue Forecast (2021-2026)13.2.3 North America Human Interleukin-2 (IL-2) Size Forecast by County (2021-2026)13.3 Europe Market Size Forecast (2021-2026)13.3.1 Europe Human Interleukin-2 (IL-2) Sales Forecast (2021-2026)13.3.2 Europe Human Interleukin-2 (IL-2) Revenue Forecast (2021-2026)13.3.3 Europe Human Interleukin-2 (IL-2) Size Forecast by County (2021-2026)13.4 Asia Pacific Market Size Forecast (2021-2026)13.4.1 Asia Pacific Human Interleukin-2 (IL-2) Sales Forecast (2021-2026)13.4.2 Asia Pacific Human Interleukin-2 (IL-2) Revenue Forecast (2021-2026)13.4.3 Asia Pacific Human Interleukin-2 (IL-2) Size Forecast by Region (2021-2026)13.5 Latin America Market Size Forecast (2021-2026)13.5.1 Latin America Human Interleukin-2 (IL-2) Sales Forecast (2021-2026)13.5.2 Latin America Human Interleukin-2 (IL-2) Revenue Forecast (2021-2026)13.5.3 Latin America Human Interleukin-2 (IL-2) Size Forecast by County (2021-2026)13.6 Middle East and Africa Market Forecast13.6.1 Middle East and Africa Human Interleukin-2 (IL-2) Sales Forecast (2021-2026)13.6.2 Middle East and Africa Human Interleukin-2 (IL-2) Revenue Forecast (2021-2026)13.6.3 Middle East and Africa Human Interleukin-2 (IL-2) Size Forecast by County (2021-2026)14 Research Findings and Conclusion15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Author Details15.3 Disclaimer

Enquire for customization in Report @https://www.qyresearch.com/customize-request/form/1540624/global-human-interleukin-2-il-2-industry

Report Objectives

To carefully analyze and estimate the size of the global Human Interleukin-2 (IL-2) market. To clearly segment the global Human Interleukin-2 (IL-2) market and estimate the market size of the segments. To provide details about key strategies adopted by leading players of the global Human Interleukin-2 (IL-2) market. To help readers understand the current and future market scenarios. To provide information about the latest trends of the global Human Interleukin-2 (IL-2) market and its key segments. To assess the contribution of each region or country to the global Human Interleukin-2 (IL-2) market. To provide information on important drivers, restraints, and opportunities of the global Human Interleukin-2 (IL-2) market. To accurately calculate the market shares of key segments, regions, and companies in the global Human Interleukin-2 (IL-2) market.

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

See the original post here:
Human Interleukin-2 (IL-2) Market Study for 2020 to 2026 Providing Information on Key Players, Growth Drivers and Industry Challenges - Cole of Duty

Recommendation and review posted by Bethany Smith

According to a report titledGlobalGene TherapyMarketpublished byFior Markets, the market explores new growth possibilities from 2020 to2025. The research report affords a number one review of the business enterprise inclusive of characterizations, companies, displays and organization chain shape. This recently published take a look at statistics including key segmentation of the globalGene Therapymarket on the basis of product type, application, and geography (country/region). The market evaluation is recommended with market trends research, evaluation additionally covers each the winning and earlier cutting-edge market developments, drivers and barriers faced through the market.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/376052/request-sample

Segmental Analysis:

The report provides the division of the overall market into different regional segments. The market presence of manufacturers and key players has also been studied. The other major segmentations on the globalGene Therapymarket are based on the product types and end-user applications. This study categorizes the worldwide product breakdown knowledge by makers, area, category and presentations, additionally tracks the marketplace, chances, and tasks. The growth of each segment provides an accurate calculation and forecast of sales by types and applications, in terms of volume and value for the period between 2020 and2025.

Major market leaders included:Spark Therapeutics LLC, Bluebird Bio, UniQure N.V., Juno Therapeutics, GlaxoSmithKline, Chiesi Farmaceutici S.p.A., Bristol Myers Squibb, Celgene Corporation, Human Stem Cell Institute, Voyager Therapeutics, Shire Plc, Sangamo Biosciences, Dimension Therapeutics and others.

The market has been segmented into regions to identify growth opportunities market such as:North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

The competitive landscape chapter of the globalGene Therapymarket report presents key information about market players such as company overview, total revenue (financials), market potential, global presence, sales and revenue, market share, prices, production sites and facilities, products offered, and strategies adopted. Furthermore, the statistics and data collected are graphically presented in the globalGene Therapymarket size and trends research report. It highlights the command and drivers influencing the market. This market research report estimates the size of the market, sales, price, revenue, gross margin and market share, cost structure and growth rate. It additionally throws light on their crucial business aspects such as production, areas of operation, and product portfolio.

BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.html

What Insights Does TheGene TherapyMarket Report Provide To The Readers?

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

View More Information @https://www.marketwatch.com/press-release/global-gene-therapy-market-2020-overview-manufacturing-analysis-development-status-competitive-analysis-to-2025-2020-04-21

Read this article:
Gene Therapy Market 2020 Rising Recognition with its Global Trends by 2025 - Research Columnist

Recommendation and review posted by Bethany Smith

What is the impact of Covid-19 crisis on the Indian pharma industry?India has an important position in the global pharmaceutical sector as it is the largest provider of generic drugs globally. In the first 9 months of FY20, India exported pharma products worth US$15.6 bn and imported pharma products (mainly bulk drugs and intermediates) worth US$5.0 bn.

2 With the Lockdown imposed in India, what were the operational issues faced by pharma companies?There are numerous operational issues faced due to lockdown restrictions. Firstly, there is limited availability for cargo flights for finished goods export due to which air freight have gone up by ~4x. This has also affected the supply of non-essential drugs to customers. Secondly, raw materials and intermediaries cargo which are imported via shipping lines are kept quarantined at seaports for 14 days before being allowed for further inland movement. As on April 6, 2020, pharma raw materials and finished goods worth over USD 1bn were stuck at the ports on account of these constraints. Thirdly and more specific to manufacturing, transportation of ancillary supplies like packaging materials has been affected. Further non-availability of contractual workers has led to a shortage of manpower in other ancillary activities related to production.

Most of these challenges are likely to see resolution with the lifting of lockdown restrictions in the coming days and weeks.

4. How will the new guidelines on Lockdown exemption from Ministry of Home Affairs (MHA) help the industry?Lockdown exemption after April 20, 2020 provided by latest MHA guidelines will allow manufacturing units to remain operational and help in addressing some of these issues as pharmaceutical industry and its ancillary industries have been notified in essential category. In the initial days, the ports will have to handle higher cargo which may lead to temporary congestion, but the situation is expected to ease with time. 5.What are the immediate focus areas for pharma companies today?After relaxation in lockdown measures, the immediate focus would be to ramp up production levels, exports and resume supplies to domestic market so that the temporary shortfall caused by reduction in supplies could be compensated. An evaluation of near-term liquidity requirements and possible sources as further clarity emerges is a task that is likely to continue. Also, it is very important that companies continue to ensure proper preventive measures for safety of their employees working in manufacturing units.

6.How can these companies improve their near-term liquidity requirements during these times?The export-oriented units should actively follow up for liquidation of Merchandise Exports from India Scheme (MEIS) scrips for payment of duty or sale in open market and GST refunds, which are expected to get processed faster based on governments direction to Central Board of Indirect Taxes and Customs (CBIC). Also, depending on their liquidity requirements, the companies can avail moratorium on loans and reassessment of their working capital limits.7

7.How are pharma companies ensuring safety and well-being of the employees and other workers in manufacturing facilities?The pharma companies need to comply with regulatory requirements of (United States Foods and Drug Administration) USFDA, UK Medicines and Healthcare products Regulatory Agency (UKMHRA) and other regulatory agencies and therefore, maintain high standards of workplace hygiene and safety. The manufacturing units have been equipped with necessary temperature monitoring devices for early identification of symptoms for COVID-19 in employees, with social distancing and sanitization are being strictly implemented by companies for the workforce within the plant, in canteens and transit buses. Also, Indian Pharmaceutical Alliance and its member companies have come together and developed Best Practices document to safeguard employee safety in pharmaceutical manufacturing.

Read the rest here:
Post relaxation in lockdown, the focus for Pharma would be to ramp up production : Ramkumar SV - ETHealthworld.com

Recommendation and review posted by Bethany Smith

More men than women have fallen severely ill or died from COVID-19, and now two clinical trials will probe whether sex hormone differences might explain the trend, The New York Times reported.

Since the COVID-19 pandemic first emerged in China, men around the world have been more likely to require intensive medical care or die from the disease than women, according to the Times report. For instance, men make up about 75% of the COVID-19 patients in intensive care or on ventilators at Cedars-Sinai Medical Center in Los Angeles, Dr. Sara Ghandehari, a pulmonologist and intensive care physician, told the Times. And as of early April, infected men in New York City were dying at about twice the rate of infected women, according to NPR.

The trend may be related to the high prevalence of heart and lung conditions in men, who also generally smoke cigarettes, consume alcohol and are exposed to outdoor air pollution at higher rates than women, Sarah Hawkes, professor of global public health at University College London, told NPR on an episode of Morning Edition. In addition to these factors, though, "there's quite a lot of good evidence that ... female immune systems are essentially a lot stronger," she added.

Related: 10 deadly diseases that hopped across species

The sex hormones estrogen and progesterone, which women produce in larger quantities than men, help to regulate the female immune system and may grant women special resistance against infections and harmful immune system responses, the Times reported. With that in mind, scientists at Cedars-Sinai and the Renaissance School of Medicine at Stony Brook University plan to treat small groups of COVID-19 patients with the hormones, to see if they make a difference.

"We may not understand exactly how estrogen works [to counteract COVID-19], but maybe we can see how the patient does," Dr. Sharon Nachman, the principal investigator of the Stony Brook University trial, told the Times.

The Stony Brook trial will include 110 patients with confirmed or presumed cases of COVID-19 who develop at least one serious symptom, such as high fever, shortness of breath or pneumonia, but do not yet require mechanical breathing support through intubation, according to ClinicalTrials.gov. All men ages 18 and older may enter the trial, as well as women ages 55 and older (women's estrogen levels tend to decline after menopause.) Half the participants will be treated with an estrogen patch placed on their skin for one week, while the other half will receive standard medical care.

Previous research suggests that extra estrogen could help clear the virus from the body, as well as support repair of damaged tissues once the COVID-19 infection begins to subside, Nachman said.

Participants in the Cedars-Sinai trial will receive progesterone, rather than estrogen, as progesterone may have anti-inflammatory properties and could prevent the onset of a so-called cytokine storm, wherein inflammatory chemical signals go haywire and damage the body, Ghandehari told the Times. The study will include 40 hospitalized men with mild to moderate COVID-19 infections. Half of those men will receive two shots of progesterone a day for five days. Both the estrogen and progesterone trials will monitor the severity of patients' illnesses through time, comparing the treated groups with the untreated groups.

Both trials bank on the idea that heightened levels of estrogen and progesterone may help the body fight COVID-19 infection, but not all the data supports that notion, Sabra Klein, who studies sex differences in viral infections and vaccination responses at the Johns Hopkins Bloomberg School of Public Health, told the Times.

"Older men are still disproportionately affected" by COVID-19 compared with older women, whose hormone levels dip dramatically following menopause, she said. "That suggests to me it's got to be something genetic, or something else, that's not just hormonal," she said. That said, infusions of estrogen and progesterone may still modulate the male immune system in a beneficial way, Klein added.

"You could get a beneficial effect in both men and women," she said. "But if women are better at recovery at 93 years old, I doubt it's hormones."

Originally published on Live Science.

The rest is here:
Doctors are testing whether estrogen could help men fight COVID-19 - Live Science

Recommendation and review posted by Bethany Smith

Period acne , or a flare-up of acne every month which coincides with the occurrence of your period, is not something so uncommon. Along with pollution, makeup, sun exposure and so many other external factors, it is important to understand what happens to your skin during periods. Just before your period date, the levels of female sex hormones fluctuate and these fluctuations may stimulate oil glands to increase oil production and results in acne breakouts. These hormonal fluctuations may also be responsible for other fun period things like, moodiness and sore breasts. Overall skin tends to be more sensitive during periods and its hard to prevent acne for good but can be minimised.

The hormones fluctuate continuously throughout the menstrual cycle, the duration of which on an average is 28 days in a woman. The levels of female sex hormones, estrogen and progesterone rise during the first and last half of the menstrual cycle, respectively. As you approach your periods the level of both these hormones fall but the level of testosterone, a male hormone which is produced in small amount in females remains constant. Thus the level of testosterone being relatively higher before and during your periods. Due to these hormonal shifts, a females skin undergoes all sorts of changes.

The secretion of sebum from sebaceous glands is stimulated by increased progesterone during the middle of menstrual cycle. Rise in the level of testosterone before and during periods also stimulates the sebaceous glands and thus more sebum is secreted. This increased sebum effects different women differently. For some, may produce a healthy glow on the skin, whereas in others, due to excess oil along with dirt, debris and dead skin cells the skin pores become clogged and cause premenstrual acne.

Sometimes, the immune system produces a reaction to Cutibacterium acne, an acne causing bacteria and this immune reaction to the bacteria and its metabolites results in inflammation accompanying pimples before periods.

Acne thats related to period is more likely to flare up during the week leading up to period or during period. It tends to clear up or improve when period is ending or over. And if you already have acne, then you might notice it getting worse during this time.

A pimple is not just a pimple, these are different types of blemishes. These are Blackheads, Whiteheads, Papules, Nodules, Cyst and knowing the difference between them , can narrow down the best acne treatment.

1. Birth Control Pills :-Increase a protein (Sex Hormone Binding Globulin , SHBG) in blood which soaks free testosterone. Thus less amount of available testosterone is there for causing acne. Also increases estrogen level. But be patient, as there is initial increase in acne on using these pills for three to four months but this subsides as the body adjusts to the pills. Before using, take advice from your doctor.

2. Spironolactone :-It is an anti-androgen drug. It reduces the level of testosterone which reduces oil production. It may not suit all women, hence, always consult your physician.

3. Weight loss :-Obesities reduces Sex Hormone Binding Globulin, SHBG and also increases testosterone. Anything, which reduces SHBG , may result in acne. Thus eat a well balanced and healthy diet and avoid junk food. Also follow a exercise routine and maintaining an optimum and healthy weight may help in controlling acne before period.

a. Wash your face two to three times a day with oil free cleanser

b. Use an Over the Counter anti-acne cream to remove excess oil

c. Avoid makeup, containing oil

d. Remove makeup and clean your skin before going to bed

e. Take a shower after exercising

5. Reduce your stress level.

6. Isotretinoin:-If other treatments havent worked for you or you suffer from severe cystic acne, then try this. It is a vitamin A derivative. The drug may cause various side effects and is not safe in pregnancy. Thus, before using , discuss all risks and side effects with your physician.

Your doctor may prescribe you low dose tetracycline for five days, which you may use few days before beginning of your period.

While breakouts may annoy you as an adult but acne typically lessen after a certain age, because with age the amount of hormones the body produces begin to decrease.

Period acne can be difficult to prevent completely. But some simple steps you can take to keep your skin relatively clear and healthy.

First of all, mix baking soda with water and make a paste.

Applying this paste on the face and let it dry.

When it dries well, wash the face with lukewarm water.

This vitamin capsules may prove to be a better option for curing acne scars.

Break the capsule of vitamin E and apply it on acne scars.

You can use this remedy once a day.

Citric acid is believed to be very beneficial in reducing irritation, removing scars and removing wrinkles in the skin.

Aloe vera gel works like magic to remove blemishes.

Sleep using this gel at night and wash face in the morning.

Results will start appearing soon.

Some other home remedies :-

a. Tea tree oil.

b. Turmeric.

c. Honey.

d. Warm compress.

e. Warm green tea bag.

f. Cold compress.

g. Neem facepack.

Link:
Periods and Acne: Are They Related ? - Krishi Jagran

Recommendation and review posted by Bethany Smith

Director General of Health Ashley Bloomfield has had to walk back comments made by himself and the prime minister yesterday about the country having achieved elimination.

New Zealand has been hailed in international media including TheNew YorkTimesand TheDaily Telegraphas having won the battle in eliminatingCovid-19.

While elimination has been achieved at alert level four giving Dr Bloomfield the confidence to move the country into level three the war has not been won.

At yesterdays daily press conference Bloomfield was asked whether New Zealand had achieved elimination.

It was his answer that weve achieved [elimination] through alert level 4 and the prime minister chipping in that New Zealand currently had eliminated the virus that resulted in yesterdays confusion.

Realising the waters had been muddied, Bloomfield arrived at Parliament today armed with a clarification.

Asked whether he accepted yesterdays remarks had given the country and the rest of the world a false impression, and whether he was concerned New Zealanders would be breathing a sigh of relief at a time they should still be vigilant, Bloomfield didnt mince his words.

I can just clarify we havent eliminated it, and we havent eradicated it.

He said elimination is about having a low number of cases, and a knowledge of where theyre coming from and identifying people early.

Then its a case of stamping out the virus and continuing to maintain strict border restrictions to be sure no new cases are being imported.

Elimination is by no means eradication and the Prime Minister Jacinda Ardern said this is a situation of entering into the world of epidemiologist-speak.

And they know well what each of these terms mean in a health sense, but of course in an every day sense they mean, often, something different.

Elimination doesnt mean zero cases we will have to keep stamping Covid out until theres a vaccine, she said.

Nationals health spokesperson Michael Woodhouse said Bloomfield probably felt the need to clarify on behalf of the prime minister.

This underscores the importance of talking in plain English. The public are not epidemiologists, they dont have the same information the prime minister has and its really important they get on the same page, talk in English, and make it clear to New Zealanders where were at and how weve got to stay there.

Bloomfield finished todays media conference doing his best to unmuddy the waters.

Well I hope my explanation today has helped to clarify if there was mud yesterday, the water is clearer today and I hope you all have a good understanding of that and New Zealanders do.

Like many people today, Bloomfield said he too enjoyed a take-away coffee but he warned how important it is not to undo the good work that has already been done.

And that means not congregating with friends outside cafes or restaurants.

Read the rest here:
Famotidine heartburn drug is being tested in NY hospitals for Coronavirus Treatment - News Brig

Recommendation and review posted by Bethany Smith

Importance Of Maintaining Normal HGH Levels In Adults

While most individuals may associate the term HGH with the growth of organs and tissues throughout childhood, it is also a vital substance for older adults. As an individual grows in age after they have reached their third decade of life, they experience a natural reduction in the amount of this hormone that is produced by the pituitary gland in the brain. Changes that take place in an individuals body that may be attributed to a natural decrease in human growth hormone secretion may include: Increased quantity of adipose tissue, especially in the abdominal area Reduced hair and or nail growth Decreased levels of energy and stamina Reduced vision Foggy memory Inability to focus Weakened immune system Decreased muscle mass and strength Reduced ability to control blood sugar levels Poor sleep quality Greater risk of osteoporosis developmentMany of these changes related to aging and reduced secretion of growth hormone in older adults are amplified in individuals who are affected by a condition that is referred to as HGH-deficiency.

According tohghtherapydoc.com, Human growth hormone deficiency develops in an individual when their pituitary gland does not produce an adequate amount of growth hormone for their respective life stage. Maintaining normal levels of growth hormone in the years following the third decade of life is crucial to keeping vital organs and tissues healthy and maintaining an optimal quality of life.

HGH is a type of peptide hormone that is produced by an individuals body in order to promote processes of cell reproduction, cell growth, and cell regeneration. When an individuals pituitary gland secretes growth hormone, it is only available in its active form in the bloodstream for several minutes. An organ that is referred to as the liver takes the growth hormone in the bloodstream and synthesizes it into numerous substances that are called growth factors. The quantity of these growth factors experiences a parallel reduction in quantity with the reduction of growth hormone secretion as an individual grows older.Fortunately, HGH can be replaced in the body through the use of human growth hormone therapy or HRT. Treatment with the use of HRT in men is known to: Help tighten loose skin that has lost its elasticity Help treat erectile dysfunction Increase the growth of hair Improve cognitive function Reduced risk of cardiovascular diseaseTreatment with the use of HRT in women is known to: Balance out the ratio of body fat and lean muscle tissue Normalize irregular sleep patterns Increase skin elasticity Promote a strong immune system Increase bone strength, reducing the risk of osteoporosis Reduced risk of cardiovascular diseaseAn increase in the synthesis of a substance that is called collagen is how human growth hormone helps increase an individuals muscle strength and endurance. Growth factors that are produced by this hormone have an ability to increase the speed of bone regeneration in an individual, making them less susceptible to fractures and breaks. HGH helps an individual maintain a proper body fat percentage through speeding up the process of lipid breakdown or lipolysis.

Numerous actors and actresses have utilized HRT to help decrease their unpleasant symptoms that have manifested due to age-related decreases in human growth hormone secretion.Sylvester Stallone, the actor who plays the famous Rocky Balboa, has discussed his use of human growth hormone under the advice and supervision of his physician in several interviews. Sylvester does not feel that it is a magic potion of sorts, but HRT helps with his levels of endurance and reducing the amount of recovery that is required following exercise. Both of which he has claimed to place wear and tear on his body as he grows older.Actress Suzanne Somers began HRT prescribed by her physician when she didnt feel like herself anymore due to the effects of aging. She utilizes it to help protect her body against the diseases of aging, increased quality of life, and increased bone density. She explains that the benefits of HRT correlate with being prescribed the correct amount, and taking excessive amounts can be dangerous.If the symptoms of low growth hormone secretion sound oddly familiar to you as an aging adult, you may be experiencing the beginning stages of human growth hormone deficiency. While the secretion of HGH does decline over time, it should not impair the quality of your everyday life. Reach out to your physician to see if you may be able to benefit from therapy with the use of HRT.

https://www.mayoclinic.org/healthy-lifestyle/healthy-aging/in-depth/growth-hormone/art-20045735https://draxe.com/nutrition/human-growth-hormone/https://www.medscape.org/viewarticle/458624https://www.metro-md.com/why-hollywood-celebrities-use-hgh/https://ventsmagazine.com/2019/08/15/growth-hormone-use-in-hollywood/https://www.hghexpert.com/135/are-top-celebrities-using-hgh/

View original post here:
HGH And Celebrities: Why Actors Over 50 Resort To HRT - CelebMix

Recommendation and review posted by Bethany Smith

In this article, global expert in life sciences pricing and all aspects of market access, Raf De Wilde, debunks this perceived contradiction and discusses specific strategies to avoid, delay or accommodate price competition to achieve long-term sustainability.

Over the years, the threat of pricing competition has increasingly become a concern. In a Valid Insight webinar on Sustainable price competition contradiction in terms?, we discussed how price competition occurs, its potential impacts, as well as some tips for how companies can alleviate price competition.

How pricing competition occurs

If prices escalate, payers can promote pricing competition. First, they declare that certain products are therapeutic equivalents and that they prefer the cheapest version. They then request price proposals from companies and award most or all of the sales to the one with the cheapest offer. Often, payers pit two companies against each other. This tendering process has become a formalised procurement approach for several major payers.

The award criteria for tenders vary some are based solely on cheap pricing, while others consider additional criteria such as payment terms, flexibility of supply, and value-added services. Tenders also vary in terms of customer size (nationwide, regional, group/single client). Subsequently, tendering can also impact the bottom line the greater the payers buying power and the more focussed they are on cheap pricing, the greater the risk for price erosion. A country tendering all-or-nothing on the lowest price can make a company win or lose an entire market at once. It is also risky for the customer; once they award one company, competitors who are back-up suppliers may exit the market completely.

Avoiding or delaying pricing competition

A well-substantiated argument for product differentiation will deter payers from claiming that all available products are equal. If a product has a clearly demonstrated higher therapeutic value, there will be pressure on payers to prefer that product because there can be ethical repercussions to prescribing lower value treatments that produce fewer positive health outcomes just because they are cheaper.

A significantly higher therapeutic value can be typical for breakthrough products, which are rare to come by. Hence, it is highly recommended for companies to also differentiate through other features that are not easy to replicate.

Pharma companies can develop products that offer advanced administration. For instance, Merck Seronos EasypodTM is a device for injecting the growth hormone Saizen (somatropin).[2] The tools development took 10 years and involved several observational studies that highlighted improved adherence. Therefore, there are two hurdles for competitors: to develop a similar technology and then substantiate that their version of the product offers even more value. For the drug Saizen, Merck Serono was able to move out of tenders and into contracts.

Differentiation can also be achieved through innovative patient access schemes and value-adding services (e.g. diet/lifestyle programmes and patient counselling).

If avoiding pricing competition is not possible, delay it instead. Companies can argue against the illegality of prioritising commercial impact over medical impact, rely on physician lobbying, or raise the publics awareness of the risks of preferring cheaper yet potentially lower quality medications.

Handling unavoidable pricing competition

Ultimately, however, discussion about tendering always seems to make its way back onto the negotiation table. So, what can companies do when price competition can neither be avoided nor delayed?

Companies can be given pricing/tendering training in the form of a special pricing simulation computer game. Two companies (or teams) play the game, which involves 6 hypothetical client hospitals (programmed with buying behaviours and perceptions) that at the start of the game demand an all-or-nothing deal. The simulated market becomes highly competitive with the entrance of a better value product and then later a biosimilar/generic competitor. The two companies must come up with the best offer to secure a years worth of sales. As the companies place their bids (annually for 6 years), the computer chooses the most logical and attractive offer.

Based on results from more than 60 different games conducted in the last 15 years, it has been observed that the average price quickly descends over the simulated 6 years. Less experienced people tend to be more aggressive in driving down price. The lesson here is that although payers can encourage price competition, the severity of the price competition is something that the industry itself can still influence. There is the need for companies to carefully react to price changes so that the amplitude of price erosion is minimised.

To read the rest of this blog, please visit: https://www.validinsight.com/how-to-weather-pricing-competition/

See the original post:
How to weather the pricing competiton - PMLiVE

Recommendation and review posted by Bethany Smith